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Chapter 1
Introduction
1.1 Fetuin Family of Proteins
For a long time the fetuin family of proteins consisted of a set of orthologous
serum proteins in humans, sheep, pigs, cows and rodents but also in birds
and reptiles. They were variably designated fetuin in sheep, pig and cow,
α2-HS-glycoprotein (AHSG) in human, phosphoprotein of 63 kDa (pp63) in
rat or countertrypin in mouse and gerbil. However, their close sequence ho-
mology, especially a set of 12 cysteine residues at fixed distances and a fetuin
motif (LETXCHXLDPTP), indicated that fetuin, AHSG, pp63 and coun-
tertrypin emerged from a single ancestral gene and resembled counterparts
(orthologous) among these species [1, 2, 3, 4, 5].
The fetuins were classified as cystatin superfamily members because they
contain cystatin-like domains characterized by the distinct cysteine residues.
Further members of the cystatin superfamily, all sharing cystatin-like do-
mains, are the cystatins themselves, histidine-rich glycoproteins (HRG) and
kininogens (KNG). The cystatins are low-molecular-weight cysteine protease
inhibitors and prototypic for the cystatin superfamily [6, 7].
A study that aimed at systematic cloning of hepatic mRNAs corresponding
to inflammation-related genes in rat [8] revealed a second member of the
fetuin family based on sequence similarity. Sequence analysis showed that the
novel protein contained both fetuin signatures, including the set of 12 cysteine
residues at fixed distances, perfectly conserved, and the fetuin motif that is
present in a truncated version (LETGCHVL) [9]. The novel fetuin, fetuin-
B was found in rat, mouse and humans, revealing both fetuin signatures
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with a 61% overall sequence homology (strictly conserved residues) in these
species. When compared to the original fetuin, fetuin-A, fetuin-B shared 17%
of strictly conserved amino acids and 24% of similar residues. The similarity
was significant but much lower than the similarity between the rat, mouse
and human fetuin-A (58% strictly conserved residues). The sequence analysis
indicated that fetuin-B was homologous, yet, clearly different from fetuin-A.
Therefore, the novel fetuins were considered a novel entity within the fetuin
family. The two paralogous were designated fetuin-A (comprising fetuin,
AHSG, pp63 and countertrypin) and fetuin-B (alias fetuin beta) [9].
1.1.1 Protein Structure
Three major domains (D1-D3) characterize fetuin proteins. Domain D1
and D2 are tandemly arranged cystatin-like domains containing 12 cysteine
residues at fixed distances, and are followed by a unique domain, D3, that is
only loosely conserved between species [10].
In fetuin-A, domains D1 and D2 both contain dibasic motifs, db1 and db2
respectively. They are thought to account for protease-inhibition domains
at least in human and bovine fetuin-A. Additionally, domain D1 contains a
calcium, TGF-β and lectin binding sites [1, 11, 12]. Domain D3 can further
be subdivided into D3a, a hydrophobic, proline-rich N-terminal half, and
D3b, a C-terminal half including a connecting peptide, at least in humans
[1, 7, 13, 14].
The general organization of domains is maintained in fetuin-B, as shown
in Figure 1.1. However, the dibasic motifs db1 and db2 are only loosely
retained and the calcium-binding site in domain D1 is absent. Furthermore,
domain D3 does contain a proline-rich N-terminal but no connecting peptide
in the C-terminal half. However, fetuin-B contains a short homology to the
TGF-β receptor type II (depicted in Figure 1.2) and two archetypal Kunitz-
type motifs, associated with protease-inhibitory activity, within domain D1
and D2 that is only present in fetuin-A domain D2 [9]. However, none of
these domains were functionally verified.
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Figure 1.1: Alignment of rat, mouse and human fetuin-B (f-B) with fetuin-
A (f-A) from various mammals (Olivier et al. [9]). White residues on black
background indicate identical or similar residues conserved in at least 10 out
of 11 sequences. Hyphens indicate gaps; boxes represent the proposed signal
peptides. The LETXCHXLDPTP fetuin signature is underlined. The 12 crit-
ical cysteine residues are marked with a dot. A CPG tripeptide conserved in
the cystatin superfamily is double-underlined. Disulphide bonds are indicated
by a horizontal connecting line between cysteine residues; the bond connecting
the first and ultimate cysteine is noted with a dashed line: The domains D1,
D2 and D3 (D3a and D3b) are marked with broken arrows. The connecting
peptide is over-lined and marked with CP. The potential calcium-binding site
is over-lined and marked with CBS. The dibasic peptides db1 and db2 are
over-lined.
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Figure 1.2: Modeled binding of human TGF-beta to its receptor type II
(structure software Pymol 0.9V). The TGF-β binding site is depicted in green.
The homology between the receptor and fetuin-B is depicted in yellow. Note
that it is not part of the TGF-β binding site.
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1.1.2 Expression
On the mRNA Level
The tissue-specific expression pattern of fetuin-A and -B mRNA is similar.
In all cases, fetuin mRNA is predominantly expressed by the liver. However,
fetuin-A mRNA can be detected to a much lower extent in the kidney, embryo
and tongue, whereas fetuin-B mRNA expression is additionally expanded to
the lung and ovary [15].
Fetuins are differentially expressed during development. In rodents the
fetuin-A liver mRNA level exhibits a perinatal and transient increase during
early post-natal life while this only happens for fetuin-B in the mouse. In the
rat, the mRNA expression of fetuin-B plateaus and is retained in adulthood.
Furthermore, fetuins have been shown to be subject to inflammation-
associated changes in hepatic mRNA expression. Fetuin-A and -B are neg-
ative acute-phase proteins, meaning that their hepatic expression is down-
regulated in response to an inflammatory stimulus [16, 17].
On the Protein Level
Fetuins are abundant serum proteins. Unlike fetuin-A, fetuin-B expression is
twice as high in human females as in males. Like most serum proteins, fetuins
penetrate most soft tissues. In this respect, the tissue distribution of fetuin-
A and -B is similar, but the amounts vary within the given tissue. Fetuin-A
is present in the cecum, heart, placenta, skin and tongue in higher amounts
than in the colon, liver, lung, skeletal muscle, small intestine, spleen and
stomach. In comparison, fetuin-B is present in the cecum, kidney, placenta,
skin and tongue in higher amounts than in the colon, heart, liver, lung,
skeletal muscle, small intestine, spleen and stomach [15].
Two distinct forms of fetuin-B were detectable at least in the liver and
tongue. There was evidence that these reflected secondary modifications,
including limited proteolysis, differential glycosylation and phosphorylation
within the highly-expressive fetuin-B mRNA tissues [15]. However, others
propose the existence of fetuin-B splice variants [18].
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1.1.3 Genetic Organization
The genes for fetuin-A (Ahsg) and fetuin-B (Fetub) are single-copy genes
and direct neighbors on mouse chromosome 16 and human chromosome 3,
followed by other members of the cystatin superfamily Hrg and Kng as shown
in Figure 1.3.
[22857939 > [23029090 >
Dnajb11 Ahsg Fetub Hrg Kng2
Figure 1.3: Genomic context of fetuin-A (Ahsg) and fetuin-B (Fetub) on
mouse chromosome 16 (from NCBI, Entrez Gene).
Figure 1.4 illustrates the genetic organization of the fetuin genes in the
mouse. The gene for fetuin-A consists of seven exons and six introns. The
first exon begins with an untranslated region (UTR) followed by the cod-
ing region. The coding sequence ends in the last exon and is followed by a
3’UTR. Exons 1 to 3 code for the two cystatin-like domains D1 and D2.
Figure 1.4: Transcripts and products of Ahsg and fetuB genes in the mouse.
Modified figure from NCBI, Entrez Gene. Exons are numbered. Reference-
nucleotide sequences are written in blue letters, protein sequences in red let-
ters.
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The genetic organization of fetuin-B is different from that of fetuin-A. The
fetuin-B gene consists of eight exons. The first exon contains the 5’UTR only.
The coding sequence does not start until exon 2 [9]. However, two alternative
first exons encoding distinct 5’UTRs exist. These alternative transcripts were
designated isoforms 1 and 3. Isoform 2 uses the same 5’UTR as isoform 1,
but isoform 2 lacks exon 2 due to alternative splicing.
However, this data was derived from in silico cloning and needs experi-
mental confirmation.
1.1.4 Biological Role
Fetuin-A was first described in 1944 by Pedersen [19] as the most abundant
globulin in fetal bovine serum. Since then many distinct biological functions
have been proposed for fetuin-A, indicating its interaction with many diverse
target molecules. Like serum albumin, α2-macroglobulin and apolipoproteins
that are well-established carrier proteins, the binding and sequestration of
otherwise insoluble ligands also seem to be major functions of fetuin-A.
In brief, fetuin-A has been shown to influence opsonization, lipid trans-
port, cell proliferation, inhibition of the insulin receptor, protease inhibition
and hematopoietic cell homing [2]. Additionally, fetuin-A has been shown to
interfere with transforming growth factor-β (TGF-β), bone morphogenetic
protein (BMP) and hepatocyte growth factor (HGF) binding to their signal-
ing receptors [12, 20]. Furthermore, animal studies have revealed a possible
interference of fetuin-A with the signaling of lipopolysaccharide (LPS) and
tumor necrosis factor-α (TNF-α) [21, 22, 23].
Fetuin-A contains a mineral-binding structure that binds apatite micro-
crystals. Thus, fetuin-A inhibits calcification in the extracellular fluid, which
is a metastable system with regard to calcium and phosphate ions [11, 24].
The physiological function of fetuin-B needs to be elucidated. The struc-
tural homology and expression patterns of fetuin-A and -B indicate similar
but also distinct functions [15]. The structural analysis of fetuin-B revealed
no functional calcium-binding domain [11]. Genetic association studies sug-
gest a role for fetuin-B in tumor biology [18]. However, the underlying molec-
ular function has not yet been revealed. In summary, a clear physiological
function for fetuin-B was lacking at the start of this work.
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Fetuin-A-Deficient Mouse Model
Jahnen-Dechent et al. generated a mutant mouse strain deficient in fetuin-
A. These animals were vital, and fertile [25]. The calcification-inhibitory
function of fetuin-A was proven in this mouse strain by Scha¨fer et al. [24].
The fetuin-A-deficient mice revealed a mild calcification phenotype [25] or a
severe systemic calcification of vital organs, dependent on the genetic back-
ground, C57BL/6 and DBA/2 respectively. The influence of the genetic
background suggests that additional serum proteins may compensate for the
loss of fetuin. However, a hypercalcemic diet induced a soft-tissue calcifi-
cation phenotype in calcification resistant mouse strains, revealing the im-
portance of fetuin-A within the pool of inhibitory proteins. The phenotype
resembled calciphylaxis, a particularly severe calcifying disorder in end-stage
renal disease patients. In this respect, these animals were employed to study
the impact of fetuin-A on vascular calcification and atherosclerosis in chronic
kidney disease in vivo [26, 27].
Besides the defective inhibition of apatite formation in serum, a study
on metabolism in fetuin-A-deficient mice revealed that fetuin-A deficiency
contributed to the decreased body weight associated with aging and under
normal and high-fat diets. Furthermore, the level of circulating free fatty
acids, triglycerides and insulin was shown to be reduced. This was accom-
panied by improved glucose tolerance in the fetuin-A-deficient mice [28, 29].
Induced tumor studies on the fetuin-A-deficient mouse model implied
fetuin-A’s role in tumor genesis and progression. Fetuin-A contributed to
early stages of skin tumorigenesis [30], to the progression of TGF-β-dependent
tumors [31], and to the promotion of metastasis of injected Lewis lung carci-
noma (LLC) cells in vivo [32], indicating that fetuin-A contributes to tumor
promotion and suppression depending on tumor stage and entity. However,
neither C57BL/6 nor DBA/2 fetuin-A-deficient mice were particularly prone
to spontaneous tumor formation.
The calcification-inhibitory potential of fetuin-A was proven by the most
prominent phenotype of the fetuin-A-deficient mice: ectopic calcification.
Moreover, the fetuin-A-deficient mice offer an excellent opportunity to prove
the in vivo relevance of in vitro generated data on the biological function of
fetuin-A.
Up to now, there was no fetuin-B-deficient mouse model available to study
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the physiological function of fetuin-B in a biological system. This work de-
scribes the first fetuin-B-null mutant mouse model. The generation of a
fetuin-B-deficient animal model and its characterization will be described in
the following chapters. It will be shown that fetuin-B-deficient females were
infertile.
1.2 Female Reproduction
1.2.1 Oogenesis and Ovulation
In mice, primordial germ cells enter the gonads at 11.0 days post coitus (dpc).
Follicle formation begins perinatally when germ cell cysts are invaded by
pre-granulosa cells to establish individual primordial follicles. Each oocyte is
contained within one follicle surrounded by the granulosa cells that contribute
to oocyte growth and differentiation [33].
By 5 days after birth, all oocytes are diploid and contain four times the
haploid amount of DNA. They are arrested in the diplotene stage of the
prophase of the first meiotic division [34]. During this time the maternal
mRNA is transcribed that is required for oogenesis and embryonic develop-
ment [35, 36]. When females reach sexual maturity, during each reproductive
cycle, primordial follicles are recruited from the resting pool (104 primordial
follicles) to start a growth phase [37].
The growing oocyte, preceding ovulation, deposits a layer of extracellular
matrix, the zona pellucida (ZP) around the oocyte [38, 39]. It contributes to
oocyte growth, serves as a polyspermy block and promotes pre-implantation
development [40]. The murine ZP is composed of three sulfated glycopro-
teins: ZP1, ZP2, and ZP3 [41]. ZP2 and ZP3 resemble long filaments inter-
connected to each other by ZP1 [42, 41]. ZP3 binds free-swimming sperm
during fertilization [43] and triggers the acrosome reaction that is essential for
ZP penetration and subsequent fertilization. ZP2 is modified after fertiliza-
tion to prevent polyspermy. This process is called zona pellucida hardening
[44].
A hormonal stimulus provided by the pituitary, the increase of follicle
stimulating hormone (FSH), causes the oocyte to resume the final stages of
meiosis I. Only a few follicles respond to the release of FSH in each repro-
ductive cycle, which occurs every four days. The responding follicles develop
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into antral (graafian) follicles, in which the stimulated follicle cells break con-
tact with the oocyte and increase their production of high-molecular-weight
proteogycans and tissue plasminogen activator. Meanwhile, the follicle ac-
cumulates fluid, swells, and moves toward the periphery of the ovary [44].
Just before ovulation, a surge in luteinizing hormone (LH) causes nuclear
(germinal vesicle) maturation of the oocyte, preceding nuclear breakdown
(germinal vesicle breakdown) and the first meiotic division. This process
is completed by the extrusion of the first polar body containing one set of
the homologous chromosomes and a small amount of cytoplasm. The other
set of chromosomes remains in metaphase II and only resumes meiosis after
fertilization.
Oocytes arrested in metaphase II are ovulated surrounded by a mass of
follicle cells. This aggregate, associated by the previously secreted proteo-
glycans, is called the cumulus oocyte complex (COC). The follicle cells that
remain in the ovary differentiate into steroid-secreting cells that contribute
to maintaining the pregnancy.
Figure 1.5: Micrograph of an ovulated mouse oocyte at day 0.5 pc. 40x
magnification, light microscopy with differential interference optics.
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8-12 oocytes are usually ovulated during one reproductive cycle. This
process is asynchronous and requires 2-3 hours. The COC is transported by
epithelial cilia into the open end of the oviduct called infundibulum. The
section of the tube adjacent to the infundibulum enlarges and forms the
ampulla where fertilization takes place.
1.2.2 Fertilization
Once the COC reaches the ampulla, it is exposed to the ejaculated sperm.
Capacitated sperm first need to penetrate through the cumulus mass before
they reach the zona pellucida. As described earlier, sperm bind to ZP3 within
the ZP, most probably to specific O-linked oligosaccarides attached to the
ZP3 polypeptide [45, 46]. ZP3-binding triggers the acrosome reaction. This
process releases hydrolytic enzymes from a secretory-vacuole-like structure,
the acrosome, that is located in the sperm’s head. The sperm’s acrosome
reaction is essential for penetrating the ZP and for subsequent fusion with
the oocyte plasma membrane [40].
Sperm that penetrate through the ZP bind to oocyte-cell-surface molecules
in order to fuse with the oocyte plasma membrane. Members of the ADAM
family on sperm and integrins on the oocyte were thought to be partners for
the binding and fusion of the plasma membranes [47, 48, 49]. More recently,
CD9, a member of the tetraspanin superfamily of integral plasma membrane
proteins that associates with integrins on the oocyte surface, was shown to
play a role in sperm-oocyte fusion [50, 51, 52], and PSG17, a member of the
immunoglobulin superfamily, may serve as a binding partner on sperm [53].
The fusion of sperm and oocyte triggers a cascade of reactions known as
fertilization. Polyspermy is excluded by the immediate change in the oocyte
surface to inhibit further fusions. Furthermore, the Ca++-dependent release
of cortical granules initiates the zona pellucida reaction in which the ZP
glycoproteins are further cross-linked, leading to zona pellucida hardening,
another block to polyspermy. At the same time, ZP3 looses its ability to
bind sperm [44].
Moreover, fertilization triggers the resumption of meiosis. The maternal
sister chromatids that were arrested in the metaphase II stage are now sep-
arated and extruded as the second polar body. Two distinct pronuclei are
formed containing the haploid maternal and paternal chromosomes. While
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both sets of haploid chromosomes are being replicated, the pronuclei move
toward the center of the oocyte. This involves modifications of the cytoskele-
ton. The membranes break down (germinal vesicle breakdown) and the chro-
mosomes assemble on the spindle. Soon thereafter, the first cleavage occurs:
the oocyte-to-embryo transition [44].
1.2.3 Parthenogenesis
Murine oocytes can initiate embryonic development in the absence of sperm.
This process is called parthenogenesis. The mouse strain LT/Sv is prone to
parthenogenetic activation (about 10% of oocytes). These embryos develop
to the gastrula stage at 7 dpc. before they die. Parthenogenetic activation
can also be induced, e.g. by deleting the c-mos gene [54, 55] or by exposing
the oocytes to activating agents such as alcohol, hyaluronidase, Ca++/Mg++-
free medium, heat or cold shock, and anesthetics.
1.3 The Mouse as a Model System
The challenge to understanding the heredity of mammalian organisms was
the driving force that led to the science of genetics. Knowledge about how
genes control mammalian development was first attained by studying the
inheritance of coat color in a variety of domestic animals. Of all mammals
studied by the early geneticists at the beginning of the 20th century, the
house mouse (Mus musculus) became the animal of choice because of its
size, resistance to infection, large litter size, rapid generation time and the
pool of mutations affecting coat color and behavior that were available.
Today large amounts of genetic information on the mouse have accumu-
lated. The mouse genome has been sequenced and assembled. A physical
map of the entire murine genome is available on nearly 300 bacterial artificial
chromosomes. It has been shown that about 99% of the murine genes have a
human homolog. This has made mus musculus a model for human genetics
and disease. Table 1.1 provides some statistical information about this model
organism.
The ability to manipulate the genome of the mouse, which was established
in the 1980s, has once more contributed to the experimental significance of
the mouse. The targeted mutation of specific genes by means of homologous
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Table 1.1: Vital statistics of the European House Mouse (Mus musculus).
Genome
Number of chromosomes 40
Diploid DNA content 2.6·109bp
Approximate number of genes 30,000-46,000
Highly repeated DNA sequences 8-10%
Reproductive biology
Gestation time 19-20 days
Age at weaning 21 days
Age at sexual maturity 6-8 weeks
Approximate weight birth 1 g
weaning 8-12 g
adult 30-40 g (female<male)
Life span 1.5-2.5 years
Average litter size 6-8
total number of litters 4-8
recombination in pluripotent embryonal stem cells is one hallmark of genetic
engineering in the mouse.
When a gene is deleted or inactivated by recombinant DNA technology,
its function can be assessed by carefully comparing the mutant and normal
(wildtype) characteristics (phenotype) of the animals. By this means data
about the in vivo function and interaction of genes can be obtained. With
most of the genome sequencing completed in 2002, genome wide gene knock-
outs are widely considered to be the next logical step towards understanding
the function of unknown genes.
1.3.1 Targeting the Mouse Genome
In classical genetics unspecifically induced mutations were used for the func-
tional analysis of genes in vivo. The generation of knockout mice by means of
gene targeting, meaning the site-directed intermolecular homologue recom-
bination of DNA, was introduced in 1988 by Capecchi [56].
A series of events had previously facilitated this technique such as the
isolation and culture of murine embryonic stem cells derived from the inner
cell mass of blastocysts in 1981 [57, 58] and the successful homologous re-
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combination of foreign DNA into the genome of mammalian fibroblasts in
1985 [59].
The injection of ES cells into the cavities of blastocysts introduces the
genetic alterations which have been performed in the ES cells into the mouse
embryo. The manipulated ES cells develop together with the cells of the
inner cell mass of the blastocyst to form a chimeric pup that is delivered by
a foster mother.
The contribution of the manipulated ES cells is revealed by the chimera’s
coat color when the manipulated ES cells and the recipient blastocyst are
derived from different mouse strains. E.g. ES cells contain the dominant
agouti gene while blastocysts carry the recessive black gene. After the mating
of the chimera with a black mouse, germ-line-transmitting chimeras give
rise to agouti and black colored mice in the F1 generations, an apparent
contradiction to Mendel’s law of uniformity. The agouti mice descend directly
from the injected ES cells. Statistically 50% of them are heterozygous for
the targeted mutation.
Mice homozygous for the targeted mutation are obtained by mating het-
erozygous F1 litter mates. The F2 generation typically consists of 50% het-
erozygous, 25% wildtype and 25% mice homozygous for the targeted muta-
tion according to Mendel’s law of segregation.
If hybrid stem cells were used, a series of backcrossing events with an
inbred strain needs to be performed to obtain a uniform genetic background.
Inbred strains are identical at all genetic loci and thereby provide insight into
the impact of the gene deletion on the phenotype.
The Gene Targeting Vector
The aim of gene targeting is the loss of an essential DNA sequence leading
to a non-functional gene. This technique is based on homologous recombina-
tion. The targeting vector contains the homologue DNA sequence, a positive
selection marker that replaces the essential DNA sequence within the ho-
mologous sequence and a negative selection marker flanking the homologous
sequence.
After transfection, the gene-targeting vector binds to the genomic ho-
mologue sequence and replaces the essential DNA sequence by the positive
selection marker. By homologous recombination the ES cells lose the nega-
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tive selection marker. Only random recombination leads to the introduction
of the negative selection marker into the genome.
The positive selection marker provides resistance against an antibiotic
agent. For instance, the neomycin phosphotransferase gene (neo) is a gener-
ally applied selection marker of E. coli origin. It provides resistance against
G418 an aminoglycosidic antibiotic. On the other hand, the negative selec-
tion marker, e.g. a thymidine gene (TK), makes cells vulnerable to ganciclovir
treatment. Thus, the administration of G418 leads to the accumulation of
recombined ES cells and the administration of ganciclovir leads to the accu-
mulation of homologously recombined ES cells. However, a genomic screening
(e.g. by Southern blot or PCR) needs to be applied to identify the homolo-
gously recombined ES cells.
1.4 Aim of the Study
The aim of this study was to determine the physiological function of fetuin-
B and to compare fetuin-B with its family member fetuin-A. Up to now the
biological role of fetuin-B was unknown; the sequence homology and tissue
distribution of fetuin-A and -B suggested similar but not identical functions.
The main focus of this study was the analysis of the physiological function
of fetuin-B in a biological system. Therefore, a fetuin-B-null mutant mouse
strain was established by gene targeting in murine embryonic stem cells. The
fetuin-B-deficient mice were characterized by analyzing their anatomy and
morphology, by evaluating physiological parameters such as body weight,
blood pressure and heart rate and by performing a clinical chemistry screen
in comparison to wildtype mice.
Additionally, tools were developed that would subsequently facilitate the
in vitro analysis of the fetuin-B protein and gene. These tools included a
recombinant fetuin-B fusion protein and reporter constructs to study fetuin-
B gene expression.
Chapter 2
Materials and Methods
The generation of the fetuin-B-deficient mice was a collaborations effort.
The fetuin-B gene targeting vector was cloned by Dr. Bernd Denecke, IZKF
Biomat, RWTH Aachen University Hospital. The ES cell transfection, blas-
tocyst injection and embryo transfer were performed in the laboratory of
Professor Hubert Schorle, Department of Developmental Pathology, Univer-
sity of Bonn Medical School. The animals were kept in the animal facility
at the RWTH Aachen University Hospital under the supervision of Dr. An-
dreas Teubner. The serum chemistry was performed by Dr. Thomas Renne´,
Institute of Clinical Biochemistry and Pathobiochemistry of the University
Medical Clinic, University of Wu¨rzburg.
Furthermore, the fetuin-B producing adenovirus was recombined and cells
were infected by the adenovirus in the S2 level laboratory of Professor Ralf
Weiskirchen, Institute of Clinical Chemistry and Pathobiochemistry, RWTH
Aachen University Hospital.
The formulas for solutions, buffers and media are listed subsequent to
each method described. Aqueous solutions were all made with distilled water.
They were sterilized by autoclaving (20 min/121◦C/2 bar). Thermo-unstable
ingredients were sterilized by filtration (0.2 µm) and added to the solution
after autoclaving.
Commonly used molecular biology-based methods were performed follow-
ing the Current Protocols in Molecular Biology [60].
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2.1 Oligonucleotides
Lyophilized oligonucleotides were purchased from MWG Biotech AG (Ebers-
berg)(0.01 µmol, HPSF purified). They were solubilized in H2O to produce
100 pmol/µl stocks.
Oligonucleotides for homologous sequence amplification:
FetuB5’Reg.3s
5’-CCGCTCGAGATGTTGGCTACTGGTTTGCTGT-3’
FetuB5’Reg.1as
5’-AGCTTTGTTTAAACCTCTAGTGAGTGGAACACAACTTCT-3’
FetuB3’Reg.1s
5’-TTGGCGCGCCTGGTTTAGTGATACGGGCCA-3’
FetuB3’Reg.1as
5’-ACGCGTCGACAAGCTGCTAGGTAGATATTTCCCAT-3’
FetuB3’Reg.2as
5’-ACGCGTCGACTGTTGAACTTTGCAAGCGACT-3’
Oligonucleotides for screening PCR and genotyping:
FetuB 8s
5’-GGGCCTGCTCAGTGTCTACC-3’
FetuB 6s
5’-CAAGTTCTAATTCCATCAGAAGC-3’
FetuB 1as
5’-GCCACCATTTCCAGAAGTCC-3’
FetuB 4as
5’-GCTTGAACGATGGGATAGGC-3’
Oligonucleotides used for fetuin-B cDNA amplification:
mFetBcDNA-EcoRI-s
5’-AGAATTCTTACAGTGGAATGGGCC-3’
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mFetBcDNA-AgeI-as
5’-ATGACCGGTGGGTGGGAGAACCAG-3’
Oligonucleotides used for sequencing:
T7-Primer
5’-TAATACGACTCACTATAG-3’ T7mod-Primer
-5’-AAATACGACTCACTATAGGG-3’
BGH-reverse
5’-TAGAAGGCACAGTCGAGG-3’
2.2 Generating a fetuin-B-deficient Mouse Strain
2.2.1 Cloning of the Gene Targeting Vector
The gene targeting vector was cloned as follows. The 5’- and 3’-homologous
sequences were amplified by PCR using the Pac clone RPCIP711A0948Q2,
library RPCI21, as a template. The reaction mix and the PCR program are
shown in Table 2.1 and 2.2, respectively. The amplified homologous sequences
were purified by using the QIAquick PCR Purification Kit (Qiagen).
Table 2.1: PCR master mix for amplifying the homologous sequences.
Primers used to amplify the 5’-homologous sequence: FetuB5’Reg.3s
and FetuB5’Reg.1as; the 3’-homologous sequence: FetuB3’Reg.1s and Fe-
tuB3’Reg.1as; the extended 3’-homologous sequence: FetuB3’Reg.1s and Fe-
tuB3’Reg.2as.
Component Final concentration
Buffer (PeqLab) 1x
dNTP 0.3 mM each
Betain 1 M
Primer s 1.2 pmol/µl
Primer as 1.2 pmol/µl
Taq (PeqLab) 0.04 U/µl
Pwo (PeqLab) 0.004 U/µl
H2O ad 50 µl
Template 1 ng/µl
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Table 2.2: PCR program for amplifying the homologous sequences using the
MJ Research PTC200 thermocycler.
T [◦C] t Cycles
68 2 min 1x
94 1 min
94 10 sec
56 1 min 10x
68 8 min
94 10 sec
56 1 min 30x
68 8 min +
10 sec/cycle
68 24 min 1x
4 ∞
Then, the 5’-homologous sequence was digested in 1x Tango buffer with
4-fold excess of PmeI (Fermentas) at 37◦C for 4 h. Thereafter, the digestion
buffer was increased to 2x Tango concentration and XhoI (Fermentas) was
added. The digestion mix was incubated at 37 ◦C for 4 h. This procedure
was also applied to the gene targeting vector.
In parallel, the 3’homologous sequence was digested by SalI (Fermen-
tas) and AscI (Fermentas) employing the enzymes 2-fold concentrated in 2x
Tango buffer over night at 37◦C.
The next morning, the digested PCR products and the opened gene tar-
geting vector were isolated from an agarose gel (QiaQuick Gel Extraction
Kit, Qiagen). The concentrations of the purified DNA fragments were esti-
mated from an agarose gel before ligating the 5’-homologous sequence to the
gene targeting vector. The ligation was performed over night at 16◦C using
a T4 DNA ligase following the manufacturer’s instructions (Fermentas).
The ligation mix was then used to transform chemically competent DH5α
bacteria (Library Efficiency, Life Technologies). The resulting colonies were
transferred to PCR tubes and corresponding tubes containing LB medium.
The PCR tubes were heated in a microwave for 2 min before the PCR reaction
mix was added. The PCR was performed according to Table 2.1 and 2.2.
Positive clones were expanded immediately using the corresponding LB
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culture. Then, a low copy plasmid midi prep (Qiafilter Plasmid Midi Kit,
Qiagen) was performed to isolate the recombinant plasmid DNA.
The gene targeting vector containing the 5’-homologous sequence was then
digested by SalI (Fermentas) and AscI as described above and purified from
an agarose gel. The purified vector’s concentration was estimated from an
agarose gel, before ligating the already prepared 3’homologous sequence to
the vector and transforming competent E. coli. The resulting colonies were
analyzed as described above.
Next, the homologous sequences were sequenced. The T7 modified se-
quencing primer was used to amplify the 5’-homologous sequence and the T3
modified primer to amplify the 3’-homologous sequence.
The knockout control vector was cloned equally to the gene targeting
vector. Only the reverse primers that were used for the amplification of the
3’-homologous sequences were different as shown in Table 2.1.
2.2.2 Gene Targeting in Embryonic Stem Cells
Culturing Embryonic Stem Cells
The ES cells, Knut 1 (129/SvJ x C57BL/6) and BAA (C57BL/6) were
thawed at day -3 and passaged 1:3 at sub confluence (day -1) onto a layer
of mouse embryonal fibroblast (MEF/feeder cells). At day 0 fresh media
was added to the cells, three to four hours before harvesting the cells for
electroporation.
Preparation of the Targeting Vector
60 µg of the Fetuin-B knockout vector were linearized with the restriction
enzyme PvuI (Fermentas) in a final volume of 3 ml. Subsequently, an aliquot
was checked on a 0.7% agarose gel for complete digestion. The linearized
vector DNA was purified by phenol/chloroform extraction, precipitated using
3M sodium acetate pH 5.2 and washed twice with 70% ethanol. The vector
was stored in 70% ethanol at -20◦C until transfection.
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Electroporation
The ethanol was removed from the linearized targeting vector and the DNA
pellet was air dried before it was dissolved in PBS in a final concentration of
0.5 µg/µl.
The ES cell dishes were rinsed twice with PBS (w/o Ca and Mg) and
the cells were trypsinized for 5min with 1x Trypsin-EDTA (PAN). The cells
were pipetted vigorously to prepare a single-cell suspension and subsequently
centrifuged (250 g/5 min). The cell pellet was then resuspended in PBS (10
ml/10-cm dish) and counted. 1.2 · 107 cells were transferred to falcon tubes
and pelleted by centrifugation (250 g/5 min). The cell pellet was resuspended
in 750 µl RPMI w/o phenol red.
25 µg (50 µl) of the targeting vector were added to the cells. The mixture
was transferred to an electroporation cuvette and placed in the electropora-
tion chamber (BioRad: Gene Pulser). A single pulse (240 V/500 µF) was
applied. The cells were incubated for 5 min at RT before they were resus-
pended in 30 ml ES medium. The content of one cuvette was transferred to
three 10-cm dishes containing feeder cells.
Positive and negative selection:
24 h after electroporation (day +1) the positive selection was started by
changing the culture media to selection media containing G418 (250 µg/ml
active substance). Until cryo-preservation, the selection media was replaced
every day. Negative selection was started at day +5 by supplementing the
selection media with ganciclovir (2 µM final concentration).
Following controls were employed:
The transfection efficiency control: 1 · 103 transfected cells without se-
lection media per 10-cm dish.
The Ganciclovir enrichment control: 0.5 · 106 transfected cells treated
with G418.
The positive selection control: 1 · 105 non-transfected cells treated with
G418.
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Picking and Expansion of ES Cell Colonies
At day +8 three 96-well plates were prepared with feeder cells. Before start-
ing the colony picking procedure the feeder cell medium was aspirated and
replaced by 100 µl ES cell medium per well. A second 96-well plate was taken
and filled with 35 µl of trypsin-EDTA solution. The culture dishes containing
the ES cell colonies were washed twice with 5 ml PBS and then filled with 10
ml of cold PBS. A microscope was used to pick individual colonies with a 200
µl micropipettor tip in a small volume of PBS. The colonies were transferred
to individual wells of the trypsin-EDTA containing dish. After finishing with
one dish it was placed in the incubator (37◦C/3-5 min). Then, 50 µl of ES
cell medium was added to each well. Using a multichannel pipettor, the ES
cell colonies were dissociated by pipetting up and down. The content of one
well was then transferred to the previously prepared feeder cell containing
96-well dishes. The cells were incubated for 2-3 days before they were pas-
saged 1:3. The content of one well was transferred to three wells on three
96-well dishes. Two of these dishes were cryo-preserved while the third plate
was again passaged 1:3 on three gelatinized 96 well plates and let grown until
confluence. These feeder cell-free plates were used for DNA analysis.
ES cell medium:
500 ml DMEM 4.5 g/l glucose, glutamax, sodium
pyruvate, Gibco
75 ml FCS ES cell tested, Hyclone
6 ml L-glutamine 100x, Gibco
6 ml non-essential amino acids Gibco
6 ml penicillin/streptomycin 100x, Gibco
1 ml Leukemia Inhibitor Factor Chemicon
1 ml 2-mercaptoethanol 50 M, Gibco
Feeder cell medium:
500 ml DMEM 4.5 g/l glucose, glutamax, sodium
pyruvate, Gibco
50 ml FCS Gibco
5 ml L-glutamine 100x, Gibco
5 ml non-essential amino acids Gibco
5 ml penicillin/streptomycin 100x, Gibco
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2.2.3 DNA Extraction from Cells in 96-Well Plates
The ES cells were grown on gelatin-coated 96-well cell culture dishes until
confluence. The cells were washed with PBS. Then 50 µl lysis buffer was
added per well. The 96-well dishes were sealed with Parafilm and incubated in
a humid chamber over night at 56◦C. Thereafter, the chamber was allowed to
cool to RT. For DNA precipitation, 100 µl ethanol (abs.) were added to each
well. Then the 96-well dishes were incubated for 2-3 h at RT. Subsequently,
the DNA appeared as a filamentous precipitate that was attached to the well
walls. The buffer was removed by carefully inverting the 96-well dishes. The
DNA was washed twice with 80% Ethanol (100 µl/well) and air dried for
30-45 min at RT and either stored covered with 80% Ethanol at -20◦C or
assessed immediately.
For DNA analysis the precipitate was eluted in 32 µl H20 by gently shaking
the 96-well dishes. 3 µl of the eluted DNA were assayed in the succeeding
screening PCR.
Lysis buffer:
10 mM Tris (pH 7.5)
10 mM EDTA
10 MM NaCl
0.5 % sarcosyl (w/v)
Add 1 mg/ml Proteinase K just before use.
2.2.4 PCR Screening
A multiplex PCR was used to screen for homologous recombined ES cells.
The PCR was performed in a 96-well plate (Abgene) using 9.5 µl of the
master mix and 3 µl DNA as template. The components of the master mix
and the PCR program are given in Table 2.3 and 2.4, respectively.
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Table 2.3: Screening PCR master mix.
Component Final concentration
Buffer (Pharmacia) 1x
dNTP 0.2 mM each
Betain 1 M
FetuB1as 1.2 pmol/µl
FetuB6s 0.6 pmol/µl
FetuB8s 1.2 pmol/µl
Taq (Pharmacia) 0.04 U/µl
Pwo (PeqLab) 0.004 U/µl
H2O ad 25 µl
Template 3 µl
Table 2.4: Screening PCR program using a MJ Research PTC200 thermo-
cycler.
T [◦C] t Cycles
68 1 min 1x
94 1 min
94 10 sec
56 1 min 10x
68 8 min
94 10 sec
56 1 min 30x
68 8 min +
10 sec/cycle
68 24 min 1x
4 ∞
30 CHAPTER 2. MATERIALS AND METHODS
2.2.5 Southern Blot
The DNA isolated from ES cell clones grown on 96-well culture dishes was
transferred into a reaction tube and filled up with TE buffer to a total vol-
ume of 25 µl. A master mix containing the restriction enzyme (either SspI
(Fermentas) or ScaI (Fermentas)), the appropriate buffer and RNase A (Fer-
mentas) were prepared. 10 µl of the master mix were added to the diluted
DNA, receiving a total volume of 35 µl. The restriction was performed over
night at 37◦C. The digested DNA was loaded on a 0.7% agarose gel which
was run at 4 V/cm for 3.5 h. The gel was prepared for Southern blotting
following the Current Protocols in Molecular Biology. The Whatman 3MM
Filter Paper Wick Method was used to blot the gel. The DNA was UV-cross
linked to the membrane by employing 150 mJoule (DNA side up) and 50
mJoule (DNA side down) (GS Gene Linker, Biorad).
The probe was a 565 bp fragment of the knockout control vector digested
with SmaI (Fermentas) and NheI (Fermentas). 25 ng were employed for
radioactive labeling via α32P-dCTP integration by Exo-Klenow polymerase
(Ambion) following the instructions of the Random Primed DNA Labeling
Kit (DECAprimeTMII, Ambion). The membrane was pre-hybridized for 2
h with hybridization buffer (Ambion) at 43◦C. Hybridization was performed
over night. Following this, the membrane was washed with prewarmed 2x
SSC/0.1%SDS (2x 30 min at 43◦C) and then 0.1x SSX/0.1% SDS (3x 30 min
43◦C). Subsequently the membrane was enclosed by cera wrap and put into
a film cassette. The exposition time was 48 h.
2.2.6 Blastocyst Injection
Homologous recombined ES cell clones (Knut 1 and BAA) were expanded
(4th passage) and then injected into blastocysts derived from superovulated
Balb/c female mice as described in Manipulating the Mouse Embryo.
2.2.7 Embryo Transfer
An embryo transfer was performed in order to transfer fetuin-B-deficient mice
into the specific pathogen free (SPF) barrier of the animal facility. Therefore,
homozygous fetuin-B-deficient males were mated with wildtype C57BL/6J
females. The two-cell stage embryos were then implanted into the oviduct
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of pseudo-pregnant SPF C57BL/6J recipient females. The procedure was
performed as described in Manipulating the Mouse Embryo.
2.2.8 Animal Husbandry and Breeding
The mice were kept in the university hospital animal facility (Institut fu¨r
Versuchstierkunde, RWTH Aachen) under standardized environmental con-
ditions and a 12/12 h light/dark period. The animals were fed with standard
rodent food (Altromin Nr. 1324) and water ad libitum.
Heterozygous fetuin-B-deficient mice with mixed genetic background were
continuously mated with mice of the inbred strains C57BL/6J or DBA/2, in
order to generate two mice strains deficient for fetuin-B with different but
defined genetic backgrounds. Ten generations of backcrossing leads to a
genetic background that resembles 99,9% of the inbred genetic background.
The mating system was either based on monogamous pairs (one male
and one female per cage) or trios (one male and two females per cage),
employing either heterozygous males and wildtype females or wildtype males
and heterozygous females depending on their availability.
2.2.9 Genotyping
Isolating DNA from Tail Biopsies
Genomic DNA of tail biopsies (± 0.5 cm) of ear marked individuals was
isolated by Proteinase K digestion and isopropanol precipitation following
the protocol of Laird et al. The isolated DNA was dissolved in 200 µl TE
buffer and stored at 4◦C.
Proteinase K digestion mix:
100 mM Tris/HCl pH8.5
5 mM EDTA
0,2% SDS
200 mM NaCl
100 µg/ml Proteinase K
0.5 ml total volume/sample
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Genotyping PCR
A multiplex PCR was used to screen for wildtype and fetuin-B-deficient
alleles. The PCR was performed in PCR stripes employing 25 µl of the
master mix (Table 2.5) and 1 µl of the tail DNA. The PCR program is given
in Table 2.6.
Table 2.5: Genotyping PCR master mix.
Component Final concentration
Buffer (Promega) 1x
dNTP 0.2 mM each
Betain 1 M
FetuB4as 1.2 pmol/µl
FetuB6s 0.6 pmol/µl
FetuB8s 1.2 pmol/µl
Taq (Promega) 0.025 U/µl
H2O ad 25 µl
Template 1 µl
Table 2.6: Genotyping PCR program using a MJ Research PTC200 ther-
mocycler.
T [◦C] t Cycles
94 2 min
94 10 sec
56 30 sec 24x
68 30 sec
68 7 min
4 ∞
2.3 Analysis of fetuin-B-deficient Mice
2.3.1 Western Blot
Wildtype and fetuin-B-deficient mouse serum was analyzed by loading 0.1 µl
serum in 10 µl 1x Laemmli loading buffer on a 10% PAA gel. The protein
gels were then blotted onto a nitrocellulose membrane (Protran, Whatman,
Schleicher und Schuell) at 1.5 mA/cm2 for 45 min, using a semi-dry blotting
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device (Biorad). The transfer was evaluated by Ponceau-S staining. The
membrane was blocked for 30 min at 37◦C with blocking solution. First and
second antibody were diluted in blocking solution (for antibody concentra-
tions see Table 2.7) and incubated for 45 min at 37◦C. After each antibody
incubation the blot was rinsed 3 x 5 min in washing solution. Protein detec-
tion was achieved by chemiluminescence.
Blocking solution: Washing solution:
1x PBS 1x PBS
0.05% Tween 20 0.05% Tween 20
5% dried milk powder
Table 2.7: Antibodies and concentrations used for Western blot analysis.
First antibody Derived from Dilution Second antibody Dilution
α-mouse fetuin-A rabbit K98 1:5000 α-rabbit HRP 1:5000
α-mouse fetuin-B rabbit K319 1:4000 α-rabbit HRP 1:5000
2.3.2 Immunohistochemistry
The immunohistochemistry was performed on cryo-sections. The sections
were kept at -80◦C over night. Thereafter, the sections were incubated in
fixative at -20◦C for 5 min, and washed 2x in washing buffer (5 min each).
Next, the fixed sections were perfused by incubating them in perfusion
buffer at RT for 10 min. Then, the sections were again rinsed with washing
buffer and blocked with absorption buffer at RT for 30 min.
The primary antibody α-mouse fetuin-B (Table 2.7) was diluted in absorp-
tion buffer (1:300), spotted onto the sections and then incubated at RT for 2
h in a humidified chamber. The sections were washed 4x in washing buffer (5
min each) before the secondary antibody ALEXA Fluor 546 goat anti-rabbit
IgG ((H+L), Molecular Probes) was applied (1:500 in absorption buffer) at
RT for 1 h. Thereafter, the sections were again rinsed 4x in washing buffer.
Subsequently, the sections were carefully dried using paper tissue and
three drops of Immu-Mount (Thermo Shandon) were put onto the sections
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in order to cover them with a cover glass. After 30 min, the sections were
sealed with clear nail polish.
Fixative: Washing buffer:
50% methanol 1x PBS
50% acetone 0.05% Tween 20
Absorption buffer: Perfusion buffer:
1x PBS 1x PBS
0.05% Tween 20 0.1% Tween 20
10% FCS % Tween 20
2.3.3 Collecting Mouse Oocytes
In order to collect newly ovulated oocytes, wildtype and fetuin-B-deficient
females were mated with wildtype males. As indicator that mating had
occurred, females were checked for vaginal plug formation in the morning.
Plug positive females were subsequently sacrificed by cervical disloca-
tion. The oocytes were isolated from the ampulla, the upper part of the
oviduct. Since ovulated oocytes are surrounded by a cloud of cumulus cells,
the collected cumulus was incubated in M2 medium containing 0.3 mg/ml
hyaluronidase (Sigma) for 2-3 min to set the oocytes free. Then, the oocytes
were washed in several drops of M2 medium and further cultivated in a
KSOM microdrop culture under a layer of embryo-tested mineral oil (Sigma)
in an cell culture incubator.
A comprehensive protocol describing the dissection of the oviduct, the
isolation of oocytes from the latter and the cultivation of the oocytes is
detailed in Manipulating the Mouse Embryo [44].
Micrographs of the cultured oocytes were taken daily using light mi-
croscopy (Leitz DMIRB, Leica) with or without differential interference op-
tics. For the latter, the oocytes needed to be cultivated on glass culture
dishes. The pictures were analyzed and archived with the DISKUS software
(Karl Hilgers, Ko¨nigswinter).
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2.3.4 Primary Morphological Analysis
The primary morphological analysis was performed according to the screen-
ing protocol in Standards of Mouse Model Phenotyping which is a modified
protocol based on Fuchs et al. [61]
The protocol includes observing the mice:
• in a cage
• on the experimentator’ hand
• holding them by the neck
• suspending them by the tail
• dropping them into the cage
12 week old animals were examined. Additionally, when handling the animals
in general, a special emphasis was made on observing them according to the
protocol.
X-Ray Analysis
For X-ray analysis six and 12 months old male and female mice were anes-
thetized for a short-term with isofluran. The X-ray pictures were taken in the
”Klinik fu¨r Radiologische Diagnostik, UK Aachen” using a mammography
machine (Senographe DMR X-ray System, GE Medical Systems SA) with the
following exposition parameters: 25 kV, 35 mAs, and 1.9 x magnification.
2.3.5 Necropsy
The necropsy was performed following the instructions published in ”The
Laboratory Mouse”. Prior to collecting the organs, the mice where perfused
by injecting PBS into the left ventricle of the heart and incising the right
ventricle of the heart for blood flow.
Organs and tissue were fixed with Bouin’s solution over night, washed
excessively with tab water and stored in 70 % Ethanol.
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Bouin’s solution:
750 ml sat. ag. picric acid
50 ml glacial acetic acid
250 ml 37% formalin
2.3.6 Histology
The Bouin’s fixed organs were dehydrated using a dehydration apparatus
(Tissue-Tek VIP, Sakura):
70% ethanol 2x 1 h
96% ethanol 2x 1 h
100% ethanol 3x 1 h
Xylol 3x 1 h
Paraffine, 60◦C 4x 1h
Subsequently, the organs were imbedded in paraffin and cut into 4 µm
sections after cooling. The sections were transferred onto glass slides and in-
cubated over night at 60◦C. The next morning, the sections were rehydrated:
Xylol 3x 3 min
100% ethanol 2x 3 min
96% ethanol 3 min
80% ethanol rinsed
70% ethanol rinsed
H2O rinsed
After that, the sections were haematoxylin and eosin stained and imme-
diately dehydrated:
Xylol 3x 3 min
Heamatoxilin 7 min
H2O rinsed
Tab water, lukewarm 10 min
Eosin 10 min
80% ethanol rinsed
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100% ethanol 2x 2 min
Xylol 2x rinsed
Then, one drop of Vitroclud (Langenbrinck, Teningen) was applied in
order to cover the sections with a cover glass.
2.3.7 Weighing
In order to follow up the animals’ weight corresponding to their genotype,
three week old F2-generation animals containing all three genotypes were ear
marked, genotyped and then weighed once a week.
2.3.8 Blood Pressure Measurement
The Blood Pressure Analysis System BP-2000 (Visitech Systems) was used
to determine the mice’s blood pressure and pulse rate. One measuring ses-
sion comprised ten habitation measurements and ten subsequent recorded
measurements of systolic/diastolic blood pressure and pulse rate. One ses-
sion was performed per day. The first five sessions were training phases only.
The results of the next five sessions were used for blood pressure and pulse
rate determination.
2.3.9 Glucose Tolerance Test
The glucose tolerance test was performed following the instructions of the
Joslin Diabetes Center (http://www.whitelabs.org)
The mice were transferred to a new cage with water but without food
and fasted for 15 h over night prior to the glucose tolerance test. The next
morning, the animals were weight and four animals at a time were fixed on
the Blood Pressure Analysis System BP-2000 platform (Visitech Systems),
which they were already adapted to.
In order to determine the baseline blood glucose, the tail was nicked with
a scalpel by a horizontal cut of the very end and a drop of blood was ap-
plied to a sensor of the Ascensia Elite glucometer (Bayer). After that, the
animals were challenged by injecting 2 g/kg body weight of 20 % D-glucose
intraperitoneally with an insulin syringe and put back into their cage.
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15, 30, 60 and 120 min post glucose injection, the mice were again fixed on
the blood-pressure platform and the blood glucose was measured by sampling
blood from the nicked tail of each mouse.
2.3.10 Clinical Chemical Screening
Serum Analysis
Blood was collected by cardiac puncture after an overdoses of isofluran as
detailed in ”The Laboratory Mouse”. The blood was applied to a serum tube
and incubated for 1 h at RT. Then, the serum tube was centrifuged (1000
g/10 min) and the serum supernatant was transferred to a reaction tube.
The serum was cryo-preserved at -80◦C.
2.4 Recombinant Expression and Purification
2.4.1 Cloning Murine Fetuin-B
PCR Amplification of Murine Fetuin-B cDNA
The fetuin-B cDNA sequence was amplified by PCR using the murine cDNA
clone MGC:25848 (BC018341) as a template. Table 2.8 shows the reaction
components. Mix I and II were added 1:1 on ice. Table 2.9 shows the PCR
program. The resulting blunt-ended PCR product was purified by agarose
gel extraction (QiaQuick Gel Extraction Kit, Qiagen).
Cloning into pGEM-T
An A-tailing procedure was applied to the purified PCR product: 5 µl of
the purified PCR product plus 1 µl of Taq DNA Polymerase 10x Reaction
Buffer with MgCl2 plus dATP in a final concentration of 0.2 mM plus 5
units of Taq DNA Polymerase plus water to a final volume of 10 µl were
mixed and incubated at 70◦C for 30 min. Of this, 2 µl were employed in the
ligation reaction with Promega’s pGEM-T vector as detailed in the pGEM-T
technical manual.
The transformation of the ligation reaction was performed according to
the pGEM-T technical manual. 2 µl of the ligation reaction were employed
using high efficiency JM109 competent cells (Promega).
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Table 2.8: Murine Fetuin-B cDNA Amplification. PCR reaction mix.
Mix I
Component final concentration
dNTP 0.6 mM each
mFetBcDNA-EcoRI-s 0.3 pmol/µl
mFetBcDNA-AgeI-as 0.3 pmol/µl
Template 30 pg/µl
H2O ad 50 µl
Mix II
Component final concentration
buffer (PeqLab) 1x
Pwo (PeqLab) 0.004 U/µl
H2O ad 50 µl
Table 2.9: PCR program for amplifying murine fetuin-B cDNA using a MJ
Research PTC200 thermocycler.
T [◦C] t Cycles
95 2 min
95 15 sec
55 30 sec
72 2 min 10
95 15 sec
55 30 sec
72 2 min 30
+ 20 sec/cycle
95 15 sec
72 7 min
4 ∞
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The resulting colonies were transferred to PCR tubes and corresponding
tubes containing LB medium. The PCR tubes were heated in a microwave
for 2 min before the PCR reaction mix (Table 2.8) was added. The PCR was
performed according to Table 2.9.
Positive clones were expanded immediately using the corresponding LB
culture. Then, a plasmid midi prep (Qiafilter Plasmid Midi Kit, Qiagen)
was performed to isolate the recombinant plasmid DNA.
Sub-Cloning into pcDNA3.1-V5-His
The purified recombinant plasmid was digested by EcoRI/AgeI (Fermentas).
The excised PCR product was purified from an agarose gel (QiaQuick, Qi-
agen). The concentration of the purified PCR product was estimated from
an agarose gel before it was ligated into the EcoRI/AgeI opened eukaryotic
expression vector pcDNA3.1-V5-His (Invitrogen).
For the ligation reaction 2 µl of the prepared vector, 2 µl 10x Ligase Buffer,
1 µl Ligase (Fermentas), 5 µl water and 10 µl of the purified PCR product
were applied.
The transformation of the ligation and the analysis of the resulting colonies
was performed as described above. Additionally the purified recombinant
plasmid DNA was digested by BamHI and also XhoI (Fermentas).
Two positive clones were sequenced using the Applied Biosystems cycle
sequencing technology at the Fraunhofer IME (Aachen) using an ABI PRISM
3730 Genetic Analyzer. The Sequences were analyzed using Staden Package
software.
Sub-Cloning into the Adenoviral Shuttle Vector
The sequenced recombinant plasmid was digested by MfeI/DraIII (Fermen-
tas). The 2.5 kb fragment was purified from an agarose gel (QiaQuick, Qi-
agen) and the overhanging ends were either filled or digested by a T4 Poly-
merase reaction:
28 µl purified fragment
8 µl 5X T4 Polymerase Buffer
2 µl 2 mM dNTP mix
1 µl T4 Polymerase
11◦C for 20 min + 70◦C 10 min
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The blunt ended fragment was then purified (QiaQuick, PCR Purification
Kit, Qiagen) and its remaining concentration was estimated from an agarose
gel before it was ligated to the EcoRV (Fermentas) opened adenoviral shuttle
vector, p∆E1sp1A.
The ligation, transformation and analysis of the resulting colonies were
performed as described above. Additionally the resulting shuttle vector was
digested by BamHI and also HindIII (Fermentas).
2.4.2 Generating a Fetuin-B Transfecting Adenovirus
The construction of replication-deficient recombinant adenoviruses (Ad5) was
based on the plasmids p∆E1sp1A and pJM17 (Biosystems Inc., Toronto,
Canada) and their homologous recombination in 293 cells. The protocol is
detailed in Weiskirchen et al. [62].
2.4.3 Expression and Purification of Fetuin-B
Recombinant Expression of Fetuin-B
The virus containing supernatant of 293 cells was obtained and added to
COS-7 cells. After an over night incubation period the media was changed
to a serum-free culture and incubated for another 24 h before obtaining the
cell culture supernatant in order to purify the expressed fetuin-B protein.
Purification of Recombinant Fetuin-B
The cell culture supernatant of fetuin-B expressing COS-7 cells was collected
and filtered through a 0.45 µm filter. The His-tagged protein was purified
using the A¨KTAdesign liquid chromatography system applying 1 ml HisTrap
affinity columns from GE Healthcare following the manufacturer’s instruc-
tions. The HisTrap columns were stripped and recharged with 0.1 M NiCl2
after every run also following the manufacturer’s instructions.
The fractions containing the purified proteins were pooled and dialyzed in
1 l PBS for 2 h and 4 l PBS over night.
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Binding buffer: Elution buffer:
20 mM sodium phosphate 20 mM sodium phosphate
0.5 M NaCl 0.5 M NaCl
20 mM imidazole 500 mM imidazole
pH7.4 pH7.4
Sequencing the Purified Fetuin-B
The protein sequencing was performed at the TOPLAB (Gesellschaft fu¨r
angewandte Biotechnologie mbH, Martinsried, Germany) using an Applied
Biosystems Procise Sequencer. 10 pM standard and recombinant murine
fetuin-B each were applied at a sampling rate of 4.0 Hertz. The data were
analyzed using Smooth Degree 9, Interpolated Baseline with the following
settings: analysis limits 1 - 128; integration and baseline limits 3.20 - 19.00
min and 0.10 - 1.00 min., respectively; peak half with and peak separation
0.05 min; search length 0.10 min; RT factor 0.80 and sensitivity 1.00.
2.5 In Vitro Analysis of Fetuin-B
2.5.1 Precipitation Inhibition Assay
The calcium phosphate precipitate inhibition assay is based on the measure-
ment of radioactively labeled calcium (45Ca2+) in a saturated calcium and
phosphate solution, that incorporates into the growing calcium phosphate
precipitate [63]. Thereby, the inhibitory potential of a test protein is directly
correlated to the measured amount of the labeled precipitate, at the end of
the experiment.
The protein and serum samples were incubated with the buffered precip-
itation mix as triplicates for 90 min at 37◦C. After the incubation period
the precipitate was pelleted by centrifugation (5 min./10,000 g). The pellet
was then solubilized in 200 µl of 1 % acetic acid and subsequently mixed
with 1 ml of szintillation buffer. The measurement of the beta radiation was
measured using the beta counter Wallac 1450 MicroBeta TriLuxt.
2.5. IN VITRO ANALYSIS OF FETUIN-B 43
Precipitation reaction mix:
5 mM CaCl2
3 mM NaHPO4
50 mM Tris pH7.4
140 mM NaCl
final volume of 200 µl
2.5.2 Mink Lung Cell Reporter Assay
Mink lung epithelial cells (MLEC) stably transfected with a PAI-1/Luciferase
reporter were cultivated in geneticin medium and passaged 1:10 every three
days. For an overview see Abe et al. [64].
For the TGF-β assay, the cells were trypsinized at 37◦C for 4 min, sus-
pended in 8 ml of normal medium and pelleted by centrifugation (10 min/1700
g/4◦C). Then, the supernatant was removed and the cells were resuspended
in 10 ml normal medium. 16000 cells/100 µl were plated in each well of a
96-well cell culture dish.
Twelve hours later, the media was removed from the cells and 100 µl assay
medium were applied per well in triplicates. After an incubation period of 20
h, the cells were removed from the incubator and cooled to room temperature
for 15 min. Then, 100 µl of reconstituted Steady-Glo Luciferase Assay Buffer
(Promega) were applied to each well. After careful shaking for 6 min at RT,
175 µl of the supernatant were transferred to a white 96-well micro-titer dish
and analyzed using a beta counter Wallac 1450 MicroBeta TriLuxt.
Geneticin medium: Normal medium:
DMEM DMEM
inc. glutamine and glucose inc. glutamine and glucose
10% FCS 10% FCS
1% penicillin/streptamycin 1% penicillin/streptamycin
200 µg/mlG418
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Assay medium:
DMEM
inc. glutamine and glucose
0.1% BSA
1% penicillin/streptamycin
2.6 Promoter Analysis
2.6.1 Cloning of Reporter Constructs
The potential fetuin-B promoter sequences were amplified by PCR employing
murine genomic DNA as a template (see Tables 2.10 and 2.11). The resulting
PCR products were purified (Qiaquick, PCR Purification Kit, Qiagen) and
subsequently digested by SmaI (Fermentas) for 3 h at 37◦C. After that, the
DNA fragments were again purified and digested by KpnI (Fermentas) over
night at 37◦C.
The vector pEGFP-1 (Invitrogen) was also digested as described above.
The DNA fragments were purified and their concentration was estimated
from an agarose gel. The ligation was performed with a T4 Polymerase
(Fermentas) following the manufacturer’s instructions at 16◦C over night.
The transformation of chemically competent E.coli (DH5-α) was per-
formed by heat shock.
The resulting colonies were checked by restriction analysis (BamHI, XcmI)
of plasmid mini prep DNA. Positive clones were grown in LB medium,
thereof, the plasmid midi prep DNA was used for sequencing.
2.6.2 Transfection of Reporter Constructs
The reporter constructs were transfected by Lipofectamine 2000 (Invitrogen)
following the manufacturer’s instructions. 16 h prior to transfection 0.5-2·105
cells were seeded to 24-well cell culture dishes. The media contained FCS
but no antibiotics.
0.8 µg DNA and 2.5 µl Lipofectamine 200 were diluted in 50 µl medium
without FCS, each. Then, both solutions were mixed and incubated for
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Table 2.10: Amplification of promoter sequences PCR master mix. The
following primers were used: mFetuBProm1-s and -as for the amplification of
the first possible murine fetuin-B promoter region; mFetuBProm2.1-s and -as
for the amplification of the second possible promoter region.
Component Final concentration
Buffer (PeqLab) 1x
dNTP 0.2 mM each
Primer s 0.6 pmol/µl
Primer as 0.6 pmol/µl
Pwo (PeqLab) 0.025 U/µl
H2O ad 50 µl
Template 0.2 µg
Table 2.11: PCR program for amplifying promoter sequences using a MJ
Research PTC200 thermocycler.
T [◦C] t Cycles
68 2 min 1x
94 1 min
94 10 sec
60 1 min 35x
68 1 min
68 8 min
4 ∞
20 min before applying the resulting 100 µl to the cells. After 5 h 10% FCS
were added to the media.
The promoter activity was assayed by fluorescence microscopy 24 h after
the transfection.

Chapter 3
Results
3.1 Generating a Fetuin-B-deficient Mouse Strain
3.1.1 Gene Deletion and the Targeting Vector
A mouse-genomic PAC clone library (129/SvevTACfBR, RZPD, Germany)
was screened for the genomic Fetub sequence. A fetuin-B cDNA fragment
consisting of exons 2-8 (834 bp) was used as a probe. The identified Fetub
positive PAC clone (RPCIP711A0948Q2 library RPCI21) also contained the
entire gene for fetuin-A (Ahsg). This confirmed that the genes for fetuin-
A and fetuin-B are located in the same chromosome region (16 B1) in the
mouse genome, separated by 18.8 kb [65] and ensured that the PAC clone
contained the entire 5’-region of the Fetub gene.
The strategy for disrupting the Fetub gene was based on the pGKneo-
TV gene targeting vector, which had already been used in our group for
the targeted deletion of the Ahsg and HRG genes [25, 66]. The vector con-
tains a PGKneo-cassette, a gene employing resistance to neomycine, which
is necessary for the positive selection of transfected ES cell clones. The
PGKneo-cassette is flanked by a multiple cloning site on each side. These
enable the insertion of 5’- and 3’- homologous regions alongside the region
which is supposed to be replaced by the neo-cassette. Further features are
two thymidine kinase genes (TK) that are located upstream from the first
multiple cloning site and downstream from the second multiple cloning site.
Only in case of a non-homologous recombination would these genes be in-
serted into the ES cell genome, making the cells sensitive to Ganciclovir.
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Figure 3.1 gives a graphical overview of the gene targeting vector and the
gene deletion strategy.
Fetuin-A
E 7
E1 E2 E3 E4 E5 E6 E7 E8
5'-homology 3'-homology
ATG
  ko-vector
(pGKneo-TV)
5R3s 3R1s 3R1as5R1as
XhoI PmeI AscI SalI
TK TK
neo
FetuB
Figure 3.1: The genomic fetuin-B sequence and the fetuin-B gene targeting
vector are shown. The exons (E1-E8) and the amplified homologous sequences
are highlighted by black boxes. The primers used for the amplification of the
homologous regions are shown with red arrows. Note that the translation
start codon (ATG) will be deleted by the homologous recombination of the
gene targeting vector with the genomic DNA.
Using the fetuin-B positive PAC clone as a template, a 2.7 kb 5’ homolo-
gous region located between exon 1 and exon 2 was amplified by PCR. The
sense primer (FetuB5R3s) used contained an internal XhoI restriction site,
the anti-sense primer (FetuB5R1as) a PmeI restriction site. This permitted
the directed insertion of the 5’-homologous sequence into the multiple cloning
site of the pGK-neo-Tv vector upstream of the neo-cassette using the unique
restriction sites for XhoI and PmeI. The 3’-homologous region, located be-
tween exon 3 and exon 5, was also amplified by PCR using a sense primer
(FetuB3R1s) containing an AscI restriction site and an anti-sense primer
(FetuB3R1as) containing a SalI restriction site. The insertion of the 3’ ho-
mologous region was performed using the unique AscI and SalI restriction
sites located in the multiple cloning site downstream from the neo-cassette as
shown in Figure 3.1. Using the 5’-homologous region located between exon 1
and 2 and the 3’ homologous region between exon 3 and 5 means replacement
of exon 2 and 3 by the neo-cassette. Exon 2 contains the translation-start
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codon, that determines the ORF of the fetuin-B gene. Replacing this codon
destroys the functionality of the fetuin-B gene.
Knockout Control Vector
A knockout control vector was designed to model the recombinant fetuin-B
genetic locus. For the establishment of the screening procedure, the knock-
out control vector was used as a positive control resembling the homolo-
gously recombinated fetuin-B allele (Figure 3.2). A 3’-homologous sequence
that was extended towards the 3’-end was amplified, exhibiting the primer-
and probe-binding sites that were required for the screening for homologous
recombination.
fetuin A
E 7
E1 E2 E3 E4 E5 E6 E7 E8
5'-homology 3'-homology
neoTK
TK TKneo
fetuin-A
E 7
E1 E4 E5 E6 E7 E8
neo
-235 bp
TK
5R3s 3R1s 3R1as 3R2as5R1as
3'-homology extended
A
B
C
D
Figure 3.2: Gene targeting and knockout control vector. The genomic fetuin-
B sequence and relevant features of the gene targeting vector as well as knock-
out control vector are shown: (A) genomic Fetub sequence, (B) gene targeting
vector, (C) knockout control vector, (D) recombinant Fetub locus. Exons are
depicted by black boxes. The homologous sequences are red colored. The
primers used for amplifying the homologous sequences of the gene targeting
and the knockout control vector are shown by red arrows. TK: thymidine
kinase; neo: neomycin resistance.
The pGKneo-Tv vector containing the 5’-homologous region as described
above was used to insert the extended 3’-homologous sequence which was
amplified with the same sense primer (FetuB3R1s) as the 3’-homologous
sequence inserted into the gene deletion vector but with a different anti-
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sense primer (FetuB3R2as). The extended 3’-homologous sequence was also
inserted into the vector using the AscI and SalI restriction sites downstream
from the PGKneo-cassette.
3.1.2 Establishing the Screening Methods
PCR Screening To identify homologously recombined ES cells, a screen-
ing strategy was developed. I decided to analyze the transfected ES cells by
using a multiplex PCR, that could amplify the wildtype fetuin-B allele and
the homologously recombined fetuin-B locus simultaneously (see Figure 3.3).
Fetuin-A
E 7
E1 E2 E3 E4 E5 E6 E7 E8
5'-homology 3'-homology 
neo
neo
P1P8
P6
WT PCR product 3,4 kb
KO PCR product 2,5 kb
TK
TK
TK
TK
P6 P1
A
B
C
Figure 3.3: Fetuin-B knockout PCR screening strategy. (A) genomic FetuB
sequence, (B) gene targeting vector, (C) knockout control vector. The primer
binding sites used for the screening PCR are indicated by red arrows (P1:
FetBgenscreen1as; P6: FetBgenscreen6s; P8: FetBgenscreen8s). The wildtype
(WT) and knockout (KO) specific PCR products are revealed by red bars.
One anti-sense primer (P1), whose binding site is not present on the gene
deletion vector, and two different sense primers were used for the multiplex
PCR. One of the sense primers was wildtype specific (P8), while the other
primer was specific to the neo-cassette (P6). The primer binding sites where
chosen such that the wildtype PCR product at 3.4 kb was larger than the
homologously recombined fetuin-B locus at 2.5 kb, making the latter product
the more favorably amplified PCR product in the multiplex PCR.
The primers were assayed for specificity using mouse-genomic DNA, for
the wild type allele (Figure 3.4 lanes 2-4), and the knockout control construct
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Figure 3.4: Establishing the knockout screening PCR: Gel electrophore-
sis picture showing the specificity of the designed screening primers and the
sensitivity of the screening system. 1AS: anti-sense primer; 6S: sense primer,
specific for knockout sequence; 8S: sense primer, specific for wildtype sequence.
(lanes 8-10) as templates. The latter was employed because of its resemblance
to the homologously recombined fetuin-B allele. To simulate the screening
procedure, the knockout control vector was added to the genomic DNA in an
equimolar concentration (lanes 15, 17, 19). The sensitivity of the multiplex
PCR to detect even little amounts of DNA was tested by adding a decreasing
amount of template to the PCR.
Figure 3.4 shows that the primers are specific for the amplification of
the 3.4 kb wildtype and 2.5 kb knockout sequence as shown in Figure 3.3.
Additionally, there is an unspecific PCR product (about 1 kb in size) using
the wildtype primers (8S/1AS). However, there is no loss of specificity from
3 µg to 0.025 µg of DNA.
Verifying by Means of Southern Blot A genomic sequence analysis of
the targeted FetuB gene revealed the loss of an SspI and ScaI restriction
site and the addition of a ScaI restriction site due to the insertion of the
PGKneo-cassette. This is shown in Figure 3.5.
The SspI wildtype DNA fragment is 4 kb in size and smaller than the
knockout DNA fragment (6.5 kb) due to the loss of an SspI restriction site.
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C
Figure 3.5: Southern Blot screening strategy. (A) genomic FetuB sequence,
(B) gene targeting vector, (C) knockout control vector. Blue arrows indicate
SspI, green arrows ScaI restriction sites; the orange bar resembles the probe
at its binding site.
When looking at the ScaI restriction pattern, the wildtype DNA fragment is
3.7 kb in size and larger than the knockout DNA fragment (3.4 kb), due to
the additional ScaI restriction site that is located within the neo-cassette.
A probe was made by digesting the knockout control vector with the
restriction enzymes SmaI and NheI. A 565 bp DNA fragment of the 3’-
end of the 3’-homologous sequence was purified and analytical amounts were
analyzed by digesting with XcmI. The resulting bands (399 bp and 166 bp)
verified the purified DNA band as the correct 565 bp probe.
The screening of targeted ES cell DNA was simulated by employing mouse
genomic DNA and the knockout control vector which was added to the ge-
nomic DNA in equimolar amounts. The predicted DNA fragments were
detected in the range 5 µg to 0.5 µg by autoradiography of the Southern
blots for 74 h. This is shown in Figure 3.6.
3.1.3 Gene Targeting in Embryonic Stem Cells
30 µg of the linearized gene targeting vector was required for each transfec-
tion of Knut 1 ES cells (129/SvJ x C57BL/6J genetic background) and BAA
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3,7 kb
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Figure 3.6: Establishing the Southern blot screening: Wildtype genomic
(WT) and knockout control vector (KOC) DNA treated with ScaI (left side)
and SspI (right side). Mixed: genomic DNA and equimolar masses of the
knockout control vector resembling 5 µg, 1 µg, 0.5 µg and 0.1 µg.
ES cells (C57Bl/6J genetic Background). Two transfections were performed
for each cell type. Therefore 300 µg of the knockout vector were linearized
with the restriction enzyme PvuI and purified by phenol-chloroform extrac-
tion. Analytical amounts of the linearized knockout vector were checked for
complete linearization on an agarose gel as shown in figure 10.7. The re-
maining DNA concentration was measured (0.1 µg/µl) and 6 x 300 µl were
precipitated using sodium acetate precipitation.
After G418 selection and ganciclovir enrichment, 262 Knut 1 and 288 BAA
resistant ES cell colonies were transferred to 96-well plates. The cells were
grown to confluency and passaged to four replicate 96-well plates. One of the
replicate plates was cryo-preserved for eventual expansion of homologously
recombined ES cell clones. The other plates were used for the following
screening procedure.
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3.1.4 Screening for Recombinant ES Cell Clones
PCR Screening: The DNA extraction was performed for one of four repli-
cate 96-well dishes containing the 262 expanded G418 resistant Knut 1 ES
cell colonies and the 288 BAA ES cell colonies. The remaining dishes were
kept cryo-preserved for later analysis. The purified genomic DNA was added
to the previously established screening PCR. To assess the accuracy of the
PCR analysis, an equimolar concentration of genomic DNA and knockout
control vector was used as a positive control, simulating the wildtype and
the homologously recombined fetuin-B allele.
Figure 3.7 shows a representative result of the PCR screening. Colony
A3 (Knut 1) and H7 (BAA) carry the fetuin-B wildtype and knockout allele
which are 3.4 kb and 2.5 kb of size, respectively. The homologous recombina-
tion rate was one in 262 for the resistant Knut 1 ES cells and one in 288 for
the resistant BAA ES cells. Taking into account that the initial cell number
was 2.4 · 107 for both ES cell lines, the total homologous recombination rate
was 4.16 · 10−8.
Figure 3.7: Screening PCR showing positive ES cell clones: The PCR prod-
ucts of the positive control (PK) and the two ES cell colonies with heterozygous
fetuin-B loci (A3 and H7) are marked with a star.
Verifying by Means of Southern Blot: The PCR screening result was
further verified by a Southern blot as described in section ”Establishing the
fetuin-B Knockout Screening Methods” above. Figure 3.8 shows the Southern
Blot. It displays the expected radio-labeled bands at 6.5 kb and 4 kb for the
SspI treated, as well as 3.7 and 3.4 kb for the ScaI treated genomic DNA of
colony A3 (Knut 1) and H7 (BAA).
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Figure 3.8: Verifying homologously recombined ES cells by Southern blot: 5
µg and 0.5 µg of genomic DNA and equimolar masses of the knockout-control
vector treated with ScaI and SspI were used as positive controls. Colonies
1G7 and 3B10, both tested negative for homologous recombination by PCR,
were employed as negative controls.
Summarizing the results: The targeted deletion of the fetuin-B gene in
the two ES cell lines Knut 1 and BAA, resulted in one ES cell clone each,
tested positive for homologous recombination by PCR and Southern Blot.
3.1.5 Blastocyst Injection and Chimera
The two ES cell clones A3 (Knut 1) and H7 (BAA) where expanded and then
injected into blastocysts derived from superovulated Balb/c female mice.
Next, the injected blastocysts were transferred by uterus transfer into pseudo-
pregnant foster mothers. The data summarizing the cell injection and embryo
transfer experiments are given in Table 3.1. Of 95 transferred blastocysts,
one chimera containing BAA ES cells was derived. The chimera exhibited 50
% chimerism but did not pass on the mutation through the germ line. Even
after five attempts no offspring derived from the manipulated stem cells was
delivered.
The manipulated Knut 1 ES cells were more productive. Two chimeras,
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Table 3.1: Blastocyst injection and outcome
] of ES cell transferred pups chimera/ germ line
donors clone blastocysts % chimerism transmission
10x A3 10 6 1 male/90% 100%
Balb/c A3 10 2 1 male/80% 100%
A3 10 4 -
A3 10 - -
10x H7 10 4 1 male/50% 0
Balb/c H7 10 6 -
H7 10 3 -
H7 10 2 -
10x H7 11 1 -
Balb/c H7 11 -
H7 11 -
H7 11 -
H7 11 -
showing 80 and 90 % chimerism, were obtained from 40 transferred blasto-
cysts. In both chimeras the Knut 1 stem cells had contributed to the germ
line. The first litter, derived from chimera 1 (90% chimerism) mated with a
C57BL/6J wildtype female, was assayed for the targeted deletion of fetuin-B
(Figure 3.9). Three of ten siblings showed heterozygosity of the fetuin-B
gene, resembling the wildtype and the mutated fetuin-B allele.
Summarizing the results: Three chimeras were generated by injecting
manipulated ES cells into blastocysts. Two of these, both containing Knut
1 cells, were germ line transmitting. The chimera containing BAA cells did
not transmit these cells to its offspring. Therefore, the establishment of the
fetuin-B null-mutant mouse line was restricted to the 129/SvJ x C57BL/6J
mixed genetic background of the Knut-1-derived offspring. To develop a mu-
tant mouse strain on a pure genetic background the mice were subsequently
backcrossed to the defined genetic backgrounds C57BL/6J and DBA/2.
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2.3 kb
4.4 kb
Figure 3.9: Fetuin-B genotype analysis: tail-DNA taken from the chimera’s
first offspring was screened for heterozygous fetuin-B deficiency. Lane 1-10:
offspring, thereof 1, 4 and 9 heterozygous fetuin-B genotype; lane 11: positive
control (genomic DNA and equimolar masses of the knockout control vector);
lane 12: negative control)
3.1.6 Embryo-Transfer and Breeding
In order to keep the generated transgenic animals in a pathogen-free environ-
ment, an embryo transfer to the specific pathogen free area (SPF) of the an-
imal facility was performed. Heterozygous fetuin-B-deficient offspring of the
chimera (N1) were mated to receive homozygous fetuin-B null mutant mice
(N1/F2). Five F2 male homozygous fetuin-B knockouts were mated with
wildtype C57BL/6J females. The blastocysts were isolated and implanted
into SPF foster mothers. By this means, two male pups heterozygous for the
fetuin-B deficiency were born in the SPF. These animals resemble the second
backcrossing generation (N2) onto the defined genetic background C57BL/6J.
From here on, the breeding of the fetuin-B-deficient mice was performed in
the SPF facility aiming at generating two distinct fetuin-B-deficient mouse
strains with pure genetic backgrounds, C57BL/6 and DBA/2. The C57BL/6
mouse strain is one of the most commonly used laboratory mouse strains
often employed as genetically modified models of human diseases. However,
DBA/2 mice are prone to calcification and were shown to exhibit a strong
calcification phenotype in combination with fetuin-A deficiency. The pedi-
grees for C57BL/6 and DBA/2 backcrossing are shown in the Appendix, in
Figure 4.2 and 4.1 respectively.
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3.1.7 Confirmation of Fetuin-B-deficient Mice
The deletion of the fetuin-B gene in mice was shown on the genomic level
by PCR analysis. The effect of the targeted deletion on the level of protein
expression was assayed in blood and tissue using Western blot analysis and
immunohistochemistry (Figure 3.10). The fetuin-B protein is absent in the
blood of homozygous knockout mice and half the normal amount of fetuin-
B protein is present in the blood of heterozygous knockout mice, while the
amount of fetuin-A, which was used as reference protein, does not vary (Fig-
ure 3.10 A-C).
+/+ +/+ +/- +/- -/- -/-
0
20
40
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80
100
120
%
Fetuin-A Fetuin-B
+/+ +/+ +/- +/- -/- -/-
A
B
C
D WT KO
Figure 3.10: Fetuin-B knockout analysis on the protein level. Immunodetec-
tion of fetuin-B (A) and fetuin-A (B) in sera of wildtype (+/+), heterozygous
(+/-) and fetuin-B-deficient (-/-) mice. (C) Densitometric analysis of the
amounts of protein detected in the Western blots in A and B. (D) Immunohis-
tochemistry of the tongue. Left wildtype (WT), right fetuin-B-deficient (KO)
section. Note the bright red staining in the WT section compared to the dark
red background staining in the KO section.
3.2. PHENOTYPING FETUIN-B-DEFICIENT MICE 59
Further, no fetuin-B protein can be detected in the tissue of fetuin-B-
deficient mice, as shown in Figure 3.10D by the secretory tissue of the tongue
known to express high amounts of fetuin-B [15]. Additionally, the translation
of partial protein products were undetectable as no protein of lower molecular
weight could be detected by the polyclonal anti-fetuin-B antibody (Figure
3.10 A). Thus, the gene knockout was confirmed on the protein expression
level of serum proteins proving that the deletion of exon 2 and 3 including
the translation start codon indeed effected a true null mutation of fetuin-B.
3.2 Phenotyping Fetuin-B-deficient Mice
After five generations (N5) of heterozygous backcrossing onto the defined ge-
netic background C57BL/6J, heterozygous mice (F1-generation) were mated
to receive homozygous fetuin-B-deficient, heterozygous fetuin-B deficient and
wildtype littermates (F2). As shown in Figure 3.11 the F2 generation con-
sisted of 154 individuals, altogether 27 % homozygous fetuin-B-deficient, 25
% wildtype and 48 % heterozygous mice.
The genotype distribution was consistent with the expected mendelian
heredity ratio of 25:50:25. Therefore, these numbers indicated that fetuin-
B-deficient mice were vital and did not suffer of prenatal mortality. The F2
population was used for the following phenotyping procedure.
157total 
40 +/+ 75 +/- 42 -/-
39 f 18 m 24 f36 m25 f 15 m 
Figure 3.11: Segregation Analysis. Organization chart showing the consis-
tence of the F2-generation in numbers. +/+ = wildtype; +/- = heterozygous;
-/- = fetuin-B-deficient mice. m = male; f = female. Seven mating cou-
ples (F1), 14 heterozygous females and 7 heterozygous males gave rise to the
population.
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3.2.1 Fertility
Evaluating the fertility of fetuin-B-deficient mice had become necessary be-
cause the first matings of homozygous fetuin-B-deficient mice failed to pro-
duce any litters.
Increasing the number of mating couples still did not lead to successful
mating, while, at the same time wildtype littermates were fertile as shown
in Table 3.2.
Table 3.2: Numbers of wildtype (+/+) and homozygous fetuin-B knockout
(-/-) matings, duration and outcome. The mating of 8 female and 7 male
homozygous fetuin-B-deficient mice in a total of 13 matings (duration between
1 and 8 months) did not lead to any offspring. However, 6 female and 4 male
wildtype littermates gave rise to 88 pups resulting from 6 matings that lasted
3 to 6 months.
Mating ] of ] of mating ] of ] of pups litter
female x male matings days litters size
FetuB -/- 1 242 - - 0
2 106 - - 0
1 93 - - 0
4 84 - - 0
1 48 - - 0
4 32 - - 0
total: n=8/7 13
FetuB+/+ 2 185 2 14 7
4 106 9 74 8.2
total: n=6/4 6
To explore whether the observed reproductive failure was sex specific,
fetuin-B-deficient females were mated with heterozygous and wildtype males
and fetuin-B-deficient males were mated with heterozygous and wildtype
females. The results of these matings are shown in Table 3.3.
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Table 3.3: Outcome of fetuin-B-deficient female and male mice mated with
wildtype and heterozygous mice. Female fetuin-B-deficient mice (-/-) did
not deliver when mated with neither wildtype (+/+) nor heterozygous (+/-)
males. On the contrary, fetuin-B-deficient males (-/-) where able to father
offspring when mated to wildtype (+/+) or heterozygous (+/-) females.
Mating ] of ] of ] of ] of pups litter
female x male matings plugs pregnancies size
-/- (n=9) x +/+ (n=5) 9 9 0 0 0
-/- (n=4) x +/- (n=4) 4 4 0 0 0
+/+ (n=9) x -/- (n=9) 9 9 8 50 6.25
+/- (n=4) x -/- (n=4) 4 4 3 12 4
+/- (n=7) x +/- (n=4) 7 6 4 18 4.2
+/+ (n=4) x +/+ (n=2) 4 4 4 29 7.25
To verify the copulation activity breeding females were routinely checked
for copulation plugs in the morning. By this token no differences concerning
the mating activity of wildtype and fetuin-B-deficient males were observed.
While knockout females mated with wildtype or heterozygous males failed
to breed, knockout males readily sired offspring when mated with wildtype
or heterozygous fetuin-B-deficient females.
The concatenated protocols and the outcome of the total number of mat-
ings of the fetuin-B-deficient mice and their wildtype litter mates are depicted
in Figure 3.12.
Summarizing the results: Homozygous fetuin-B-deficient mice copulated
but failed to produce offspring. Female mice deficient for fetuin-B were in-
fertile regardless of the genotype of the mate, while fetuin-B-deficient males
were fertile. Therefore, the breeding defect was due to female infertility.
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Figure 3.12: Mating Calendar. Graphical overview showing numbers of
matings and litter birth for one year. Each mating is indicated by a black
line. Circles symbolize females, circles including an arrow symbolize male
individuals. Black closed circles indicate wildtype, black half-closed circles
indicate heterozygous and open circles indicate fetuin-B-deficient individuals.
Numbers identify each animal. The birth of litters are indicated by stars. This
graphical overview demonstrates that fetuin-B-deficient mice did not produce
any offspring when the female was homozygous fetuin-B deficient, whereas
wildtype and heterozygous fetuin-B-deficient mice delivered offspring during
the same time period.
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Oocytes
Histological evaluation of knockout uteri and ovaries did not reveal any ab-
normalities when compared to wildtype littermates (see Figure 3.18). On
both sections advancing stages of growing follicles were visible. Though,
it was questioned, if the infertility of fetuin-B-deficient females was due to
missing ovulation.
For this reason, ovulation of naturally mated wildtype and fetuin-B-deficient
females was examined by dissecting the upper part of the oviduct (the am-
pulla) at day 0.5 pc. Eight wildtype and ten fetuin-B-deficient females were
examined. Hereby, ovulated oocytes were isolated from both genotypes. The
average number of isolated oocytes per wildtype and fetuin-B-deficient fe-
male was 8 ± 3. Consequently, the female infertility could not be due to an
ovulation defect.
Figure 3.13: (A) Frequency distribution of the oocytes’ size including the
zona pellucida (n=78) and (B) thickness of the zona pellucida (n=17). Mi-
crographs of oocytes were used to measure their diameter and zona pellucida
thickness (DISKUS software).
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Figure 3.14: Micrographs of in Vitro cultivated oocytes isolated from nat-
urally mated females. Oocytes isolated from wildtype females at day 0.5
(A,B,E,F), 1.5 (I) and 2.5 pc (K). Oocytes isolated from fetuin-B-deficient
females at day 0.5 (C,D,G,H), 1.5 (J) and 2.5 pc (L). 40 x magnification, light
microspcopy with differential interference optics. Note that oocytes derived
from fetuin-B-deficient females remain in the single-cell stage and do not de-
velop into the two-cell stage of an embryo. Additionally, the morphology of
these oocytes is altered: the perivitelline compartment is not visible.
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The isolated oocytes showed reproducible differences concerning their mor-
phology. Oocytes isolated from wildtype females displayed fertilization char-
acteristics such as pro-nuclei and a pair of polar bodies (Figure 3.14 A, B, E,
F). These characteristics were not visible in oocytes isolated from fetuin-B
knockouts. Furthermore, the perivitelline compartment was not visible in
these oocytes, due to the zona pellucida that surrounded these oocytes very
tightly (Figure 3.14 C, D, G, H).
When measuring the diameter of the oocytes, including the zona pellucida,
it became obvious that oocytes derived from fetuin-B deficient mice where
smaller by 11% compared to oocytes isolated from wildtype females (92.6
µm ± 2.8 µm and 103.5 µm ± 3.8 µm). The size distribution of 78 evaluated
oocytes are shown in Figure 3.13 A. The thickness of the zona pellucida
(measured at 17 oocytes) was decreased significantly by 26% (p= 0.0003) for
oocytes isolated from fetuin-B-deficient females (Figure 3.13 B). However, the
diameter of the cytoplasm was 4-8% larger in oocytes derived from fetuin-B
deficient females than in oocytes derived from wildtype females.
Keeping the isolated oocytes in vitro enabled exploring their developmen-
tal potency as shown in Figure 3.15.
Figure 3.15: Kaplan-Meier developmental curve of oocytes. Numbers of
oocytes developing into progressive stages of pre-implantation embryos. The
Oocytes of wildtype and fetuin-B-deficient females were isolated at 0.5 dpc,
further cultivated in vitro and evaluated daily by light microspcopy with dif-
ferential interference optics.
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While 79% (48/61) of oocytes isolated from wildtype females developed
into a two-cell stage within 24 h, 98% (78/81) of the oocytes that were
isolated from fetuin-B-deficient females remained undivided. Figure 3.14
shows representative micrographs of the in vitro cultivated cells.
The three oocytes (2% totally) isolated from fetuin-B-deficient mice that
developed to a two-cell stage could further be classified as parthenogenetic.
Micrographs of these cells are shown in Figure 3.16. This data indicated,
that there was a fertilization defect.
Figure 3.16: Micrographs of parthenogenetically developed oocytes derived
from naturally mated fetuin-B-deficient females (E-H, I-L, M+N)) compared
to representative micrographs of fertilized oocytes derived from wildtype fe-
males (A-D). From left side to right side: day 0.5, 1.5, 3 and 5 pc.
.
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3.2.2 Anatomical and Morphological Analysis
Primary Morphological Analysis
The morphological analysis according to Fuchs et al. [61] yields first-line in-
formation about skeletal malformations. Fetuin-B-null mice, resulting from
heterozygous matings, showed normal behavior in their cage. Apathetic or
hyperactivity disorders were absent. Their locomotion was not altered. Fur-
thermore, no difference in size or grooming behavior was identified compared
to wildtype litter mates. By observing the mice in more detail, while sit-
ting on the experimentator’s hand, the natural habit of mice to explore their
environment was noted, always trying to achieve an upright position. Head
shape, vertebral column, pelvis elevation and tail movement appeared nat-
ural. Holding the animal by its neck the shape of the rib cage, the limbs
and also the vertebrae of the tail were free of major malformations. Visual
inspection and palpation suggested that limbs, joints, vertebral ribcage, tail
mandibles and teeth were all normal and free of gross anatomical malforma-
tions.
X-Ray Analysis of Skeletal Morphology
In order to detect putative skeletal abnormalities conventional X-ray pictures
were taken and scored for congenital bone diseases, signals of infections as
well as joint dislocations. X-ray pictures were taken of 12 and six month
old knockouts (n=6). Figure 3.17 shows representative X-ray pictures of
12 months old fetuin-B-deficient and wildtype mice. The skeletal anatomy
appeared normal. Furthermore the X-ray pictures revealed that the fetuin-
B-deficient mice did not suffer of ectopic calcification disorders like mice
deficient in the related fetuin-A protein.
Necropsy and Histology
The post-mortem examination (necropsy) of the fetuin-B-deficient mice was
performed to further characterize the clinical features of the genetic modi-
fication. In contrast to the primary morphological analysis, necropsy is an
invasive method which evaluates the organs within the body. The aim is to
identify abnormalities that are due to the genetic modification.
The necropsy was performed with matured six-month-old wildtype and
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Figure 3.17: Representative X-rays of 12 months old wildtype (A) and
fetuin-B-deficient mice (B). Note that there are neither signs for skeletal mal-
formations, nor calcification disorders, a characteristic of fetuin-A deficient
mice.
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fetuin-B-deficient males and females. Each group consisted of three individ-
uals. The fetuin-B-deficient mice revealed no gross morphological differences
when carefully compared to the wildtype litter mates. The size and weight
of the organs were inconspicuous. For histological analysis, the organs were
fixed, sectioned, hematoxylin-and eosin-stained and evaluated by means of
light microscopy. Selected representative microphotographs are shown in
Figure 3.18-3.21.
Figure 3.18 A and B show sections of the epididymis of wildtype and
fetuin-B-deficient male mice, depicting characteristic spermatozoa in the lu-
men of the epididymal ducts which are formed by epithelial lining and smooth
muscle cells. The sections of the testis in Figure 3.18 C and D show the
proceeding differentiation of the spermatogonia in seminiferous tubules sur-
rounded by Sertoli and Leydig cells, suggesting that the action of the repro-
ductive organs was not altered in fetuin-B-deficient male mice.
Figure 3.18 E and F show sections of the uteri of wildtype and fetuin-
B-deficient female mice. The uterine horns are composed of the endome-
trial epithelium, endometrial glands and endometrial stroma surrounded by
a smooth muscle layer. Sections of the ovary (Figure 3.18 G and H) show
different stages of folliculogenesis, suggesting that ovulation occurred in both
genotypes.
Figure 3.19 shows representative sections of the small intestine (A and B),
special lymphoid tissue located within the intestine, the Peyer’s patches (C
and D) and sections of the large intestine (G and H).
Figure 3.20 A and B show representative micrographs of wildtype and
fetuin-B-deficient liver sections. Both tissues are characterized by an uneven
size of hepatocytes and hepatocellular nuclei. Figure 3.20 D and E show
representative sections of the kidney. The functional structures of the kidney,
the glomeruli, as well as proximal convoluted tubules are visible and suggest
normal function. Figure 3.20 E and F show representative sections of the
pancreas and Figure 3.20 G and H of the spleen.
Figure 3.21 A and B show sections of the outer ear and of the lung (C and
D). The latter micrographs reveal physiological structures such as alveolar
ducts and bronchioles.
In summary, the fetuin-B-deficient tissue analyzed did not reveal gross
morphological abnormalities or pathophysiological conditions.
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Figure 3.18: Representative micrographs of male and female reproductive
organs: epididymis (A, B) and testis (C, D); uterus (E, F) and ovary (G,
H) of wildtype (A,C,E,G) and fetuin-B-deficient (B, D, F, H) mice (4µm HE
sections, scale bar: 200 µm).
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Figure 3.19: Representative micrographs of the intestines of wildtype (A,
C, E, G) and fetuin-B-deficient (B, D, F, H) mice: duodenum (A, B), Peyer’s
Patch (C, D), jejenum (E, F), colon (G, H) (4µm HE sections).
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Figure 3.20: Representative micrographs of liver (A, B), kidney (C, D),
pancreas (E, F) and spleen (G, H) of wildtype (A, C, E, G) and fetuin-B-
deficient (B, D, F, H) mice (4µm HE sections).
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Figure 3.21: Representative micrographs of ear (A, B) and lung (C, D) of
wildtype and fetuin-B-deficient mice (4µm HE sections).
74 CHAPTER 3. RESULTS
3.2.3 Physiological Parameters
General physiological parameters such as body weight, blood pressure and
pulse rate were measured to determine the physical condition of the fetuin-
B-deficient mice.
Weight: The weight measurement was performed weekly from three weeks
up to four months of age. Figure 3.22 shows the plotted data. The analysis
of the accumulated data revealed that there was no difference between the
weight of sex and age matched wildtype and fetuin-B knockout mice.
Blood pressure and pulse rate: Blood pressure and pulse rate were
measured using the ”BP-2000 Blood pressure Analysis System” (Visitech
Systems). Sex matched wildtype and fetuin-B-deficient mice, three months
of age were analyzed. Each group consisted of seven animals. After a training
phase, all measurements that yielded data for systolic blood pressure (SBP),
diastolic blood pressure (DBP) and pulse rate were plotted. Data series with
individual measurements missing were discarded entirely. The resulting data
are depicted in Figure 3.23.
The median blood pressure value of wildtype and fetuin-B-deficient males
was 97/71 (SBP/DBP). The median of female mice was 100/73 for wildtype
and 100/75 for fetuin-B-deficient females. The median pulse of wildtype
males (513 bpm) and fetuin-B-deficient males (499 bpm) were inconspicuous.
The median pulse of the female mice was slightly faster (577 bpm for wildtype
and 600 bpm for fetuin-B-deficient females).
Taken together the pulse rate and blood pressure measurements indicated
that the fetuin-B-deficient mice have no gross cardiovascular defects affecting
these parameters.
3.2.4 Glucose Tolerance Test
A glucose tolerance test was performed because an initial serum analysis for
glucose levels had given a hint for impaired glucose metabolism in male fetuin-
B-deficient mice. Another reason for analyzing the glucose metabolism in
fetuin-B-deficient mice was that fetuin-A has been shown to mediate insulin
receptor signaling [67, 68, 69] and fetuin-A-deficient mice showed an improved
insulin sensitivity when compared to wildtype mice [28].
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Figure 3.22: Body weight of sex matched wildtype and fetuin-B-deficient
mice. Each dot represents the mean value of weight measurements at that
day. The curve was interpolated using a non-linear regression fit of Graph
Pad Prism.
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Figure 3.23: Measurement of blood pressure and pulse rate. Every dot
represents one measurement value of age and sex matched wildtype and fetuin-
B-deficient mice (n=7 for each group: male +/+, -/-, female +/+ and -/-).
The median is depicted by a black line.
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Figure 3.24 depicts the glucose metabolism of age and sex matched wild-
type and fetuin-B knockout mice after a challenge of 2 g/kg body weight of
20 % D-glucose.
A
B
Figure 3.24: Glucose tolerance test. Comparison of glucose metabolism of
wildtype (WT) and fetuin-B-deficient (KO) males (A) and females (B). n=10
for each group. Note that there were no statistically significant differences
between the genotypes at any timepoint.
The resulting data were analyzed using an impaired two-sided t-test and
Graph Pad Prism software. The analysis revealed that the wildtype and
fetuin-B-deficient mice did not differ significantly in their glucose metabolism
(P=0.8 and 0.7 comparing wildtype and fetuin-B-deficient females and wild-
type and fetuin-B-deficient males, respectively). Thus, fetuin-B deficiency
was not associated with a diabetic phenotype of hyperglycemia or glucose
intolerance.
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3.2.5 Clinical Chemical Screening
The clinical serum chemistry screening is a diagnostic tool suitable for de-
tecting defects in organ systems, haematological disorders and changes in
metabolic pathways. Moreover, the loss of a serum protein could result in
impaired major serum functions such as for instance the coagulation system,
the osmotic pressure or homeostasis. Therefore, the primary clinical chem-
istry screen was chosen such that alterations in a broad range of conditions
could be detected with a reliable number of parameters.
Serum analysis: 19 parameters were analyzed from age matched wildtype
(n=6) and fetuin-B-deficient (n=6) sera. These parameters included indica-
tors for liver, renal, pancreas, and thyroid functions, as well as muscle, bone,
cardiovascular system and metabolic disorders.
The resulting data are shown in Figure 3.25. The data were analyzed using
a Student’s t-test. When comparing wildtype to fetuin-B-deficient sera, none
of the 20 parameters reached statistical significant differences.
Coagulation analysis: fetuin-B-deficient plasma was screened for coagu-
lation defects. Global tests were chosen that give first line information about
the function of the intrinsic coagulation system. The fetuin-B-deficient sera
were compared to sera of age and sex matched wildtype litter mates (six
individuals each, consisting of three males and three females).
By comparing the thromboplastin time (Quick), partial thromboplastin
time (PTT), and levels of Fibrinogen and anti-thrombin III no conspicuous
differences were detected in the function of the intrinsic coagulation system of
wildtype and fetuin-B-deficient mice. The thromboplastin time and the level
of fibrinogen were slightly elevated in male knockouts. Figure 3.26 shows the
data in a graphical overview.
In summary, the serum chemistry did not reveal any major alterations in
organ function or blood clotting associated with the lack of fetuin-B. The
data suggests that fetuin-B-deficient mice are basically healthy without any
severe clinical disorders.
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Figure 3.25: Clinical chemistry screening. Comparison of wildtype (black
bars) and fetuin-B-deficient (white bars) sera on a logarithmic axis (n=6 per
group). (A) Serum electrolytes: phosphate (PO4) , calcium (CA) , potas-
sium (K) and sodium (NA). (B) Enzymes as markers for liver and pancre-
atic function: glutamate oxalacetate transaminase (GOT), glutamate pyru-
vate transaminase (GPT), gamma glutamyl transferase (GGT), alkaline phos-
phatase (AP), amylase(AML), and lipase (LIP). (C) Substrates and total pro-
tein: glucose (GLUC), creatinine (CREA), urea (UREA) , cholesterol (CHOL),
triglycerides (TRIG), uric acid (HS), bilirubin (BILI) and total protein (TP).
Statistical analysis performed using two-sided Students t-test and Microsoft
Excel software.
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Figure 3.26: Blood Coagulation Parameter. Dots represent single measure-
ments. Lines represent the median values. Note that thromboplastin time was
different in male and female mice, however, this is consistent for wildtype and
fetuin-B-deficient mice.
3.2.6 Summarizing the Phenotyping Results
The initial characterization of the fetuin-B-deficient mice revealed female
infertility while the reproductivity of fetuin-B deficient males was not altered.
It was shown that oocytes derived from fetuin-B-deficient females did not
develop into two-cell embryos.
Differences in the anatomy and morphology of these mice were not found
when compared to wildtype mice. Furthermore, the fetuin-B deficient mice
showed typical physiological parameters when assayed for body weight, blood
pressure and pulse rate. The glucose metabolism was not affected by the
fetuin-B null mutation. Lastly, the serum analysis covering important func-
tional parameters of major organs suggests that fetuin-B-deficient mice are
basically healthy without any severe clinical disorders.
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3.3 Recombinant Murine Fetuin-B
Up to now murine fetuin-B was not available as a purified protein but there
was a need for the protein in order to perform functional in vitro analysis.
The aim of the following work was to produce an adenovirus that could
efficiently transfect the fetuin-B cDNA into mammalian cells for subsequent
purification and analysis of the recombinant protein.
3.3.1 Cloning Recombinant Murine Fetuin-B
The final goal was to insert the murine fetuin-B cDNA into an adenoviral
vector system. But first, the fetuin-B cDNA had to be equipped with a
constitutively active promoter and a purification tag because the adenoviral
vector system did not contain a promoter and because the fetuin-B protein
was supposed to become an easily purified fusion protein. Therefore, the
fetuin-B cDNA was inserted into the eukaryotic expression vector pcDNA3.1-
V5/His A (Invitrogen).
This vector offers a strong constitutive promoter (CMV) and it provides a
c-terminal purification tag (His) that is followed by a poly-adenylation signal.
The cloning strategy and the illustration of the employed vectors are shown
in Figure 3.27 and are explained in the following:
The mouse fetuin-B cDNA clone MGC:25848 (BC018341), which includes
the complete FetuB coding sequence, was purchased from Life Technologies,
Inc. The Fetuin-B cDNA sequence was amplified by PCR. The primers
that were used were supplied with unique restriction sites: the sense primer
contained an EcoRI restriction site and was designed to bind upstream from
the translation-start codon, and the anti-sense primer contained an AgeI
restriction site. This primer was designed to bind to the last codons of the
cDNA but excluding the internal stop codon. Figure 3.28 shows the fetuin-B
cDNA sequence and the primer-binding sites.
Subsequently, the PCR product was ligated to the pGEMT-Vector
(Promega). This vector does not have restriction sites for EcoRI and AgeI.
Consequently, by digesting the construct with these restriction enzymes, the
cloned fetuin-B cDNA sequence, beginning from the translation start codon
but missing the internal stop codon, was excised. Finally, the modified fetuin-
B cDNA was ligated to the EcoRI/AgeI linearized expression vector. By
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Figure 3.27: Sequence of cloning the fetuin-B fusion protein beginning with
the cloning of fetuin-B cDNA into the PCR product cloning vector pGEMT,
then, into the eukaryotic expression vector pcDNA3.1/V5-His in-frame with
the histidine purification tag. Finally, the fetuin-B cDNA including CMV
promoter and His-tag was cloned into the adenoviral shuttle vector which was
recombined with the adenoviral backbone vector to become a recombinant
fetuin-B containing Ad5 adenovirus.
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AGAATTCTTACAGTG
EcoRI
ACCGGTCAT
AgeI
Figure 3.28: Fetuin-B cDNA amplification primers and their binding sites
on the fetuin-B cDNA. The nucleotide sequence upstream +1 does not align
to the fetuin-B reference sequence (NM 021564), therefore, the primer was
changed accordingly. Note that the UGA stop codon was replaced by a short
linker and a His-tag to facilitate recombinant protein purification.
digesting the vector with EcoRI/AgeI the His-tag was connected as close as
two additional base triplets with the 3’-end of the fetuin-B cDNA sequence.
The complete coding sequence including the transition from the coding
sequence to the vector was sequenced, starting upstream and downstream
from the fetuin-B coding sequence within the vector sequence. This showed
firstly, that the fetuin-B coding sequence was not mutated, due to the PCR
amplification and secondly that the transition from the coding sequence to
the vector sequence coding for the His-Tag was in frame as shown in Figure
3.29.
The construct was assayed for expression of fetuin-B by transfecting
COS-7 cells and analyzing the cell culture supernatant 36h after transfection
with means of Western blotting. While there was no fetuin-B detectable in
the mock control (pcDNA3.1-V5/His A) fetuin-B was detected in the media
of pcDNA3.1-CMV-FetB-His transfected cells as shown in Figure 3.30.
After having proven the construct´s functionality the complete functional
unit consisting of the CMV promoter, the fetuin-B cDNA, the connected
His-tag and a polyadenylation signal was excised by the restriction enzymes
MfeI and DraIII (Figure 3.27). This fragment was then ligated to the EcoRV
opened shuttle vector, p∆E1sp1A.
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Figure 3.29: Consensus sequence of sequencing data (consens), and align-
ment of the resulting amino acid translation (rec) and the protein sequence
(native). The vector pcDNA3.1-CMV-FetB-His was sequenced using T7 and
BGH primers as sense and anti-sense primers, respectively. The sequenced
cDNA sequence was not mutated by the PCR amplification; furthermore, the
endogenous stop codon was excluded and the His purification tag was con-
nected in-frame with the Fetub open reading frame. The putative N-terminus
of the secreted protein is marked by the black linings.
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Figure 3.30: Fetuin-B Western blot of transfected COS-7 cells. Supernatant
(10 µl) of pcDNA3.1-CMV-mFetB-His (1) and pcDNA3.1-V5/His A (2) trans-
fected COS-7 cells. Murine serum (1:100) was applied as a positive control
(3). Right: molecular weight marker
3.3.2 Generating a Fetuin-B Transfecting Adenovirus
The recombinant shuttle vector and the adenoviral backbone vector (shown
in Figure 3.27) were homologously recombined by co-transfecting them into
293 cells. These cells produce E1 proteins, which are not encoded by the
adenoviral vector. Hence, only these cells enable the assembly of the aden-
ovirus.The virus containing supernatant was transferred to COS-7 cells. The
proper recombination of shuttle and backbone vector was assayed by detect-
ing the recombinant fetuin-B protein in the cell culture supernatant.
3.3.3 Expressing and Purifying Recombinant Fetuin-B
In order to purify the recombinant fetuin-B fusion protein, 45 x 10cm-dishes
containing COS-7 cells were treated with the fetuin-B transfecting aden-
ovirus. By this, 450 ml (serum-free) cell culture supernatant were harvested,
containing the fusion protein. Using the A¨KTAdesign liquid chromatogra-
phy system and HisTrap affinity columns from GE Healthcare, the fetuin-B
fusion protein was purified from the supernatant. Half of the supernatant
(225 ml) were pumped over the 1 ml HisTrap column (first run), then the
column was washed and the fusion protein was eluted. The second half of the
supernatant was proceeded accordingly (second run). The flow-through was
pooled and pumped over two connected 1 ml HisTrap colums (third run),
otherwise it was proceeded as before. Subsequently, the flow-through of the
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third run was proceeded as the former run. A representative chromatogram
of a purification run is shown in Figure 3.31.
Figure 3.31: Representative purification chromatogram. Red line: absorp-
tion; black line: conductivity. The absorption plateau resembles the flow
through of the cell culture supernatant, the following peak resembles the elu-
tion of proteins that had specifically bound to the HisTrap column.
Supernatant, flow-through and the pooled fractions of the purified fetuin-
B fusion protein were analyzed by Coomassie staining of a polyacrylamide
gel and by a fetuin-B Western blot, both shown in Figure 3.32A and B,
respectively.
Coomassie staining and Western blot illustrated the purification of the
fetuin-B fusion protein: firstly, the quantity of the flow-through band 1 to 4
stays the same in the Coomassie stain, while the amount of fetuin-B decreases
with every purification step as shown by the Western blot and secondly, the
Coomassie stain shows only one band in the pooled purification fraction, that
is not visible in the cell-culture supernatant, identified as purified fetuin-B
by the Western blot. The Western blot demonstrates, progressive depletion
of fetuin-B from the cell-culture supernatant. After the fourth run fetuin-B
was no more detectable in the flow-through.
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Figure 3.32: Analysis of purification products. (A) Coomassie stained poly-
acrylamide gel (25 µl sample per lane) and (B) anti-fetuin-B Western blot (10
µl sample per lane) of: 1) cell culture supernatant; 2) HisTrap flow-through
of the first run; 3) HisTrap flow-through of the third run; 4) HisTrap flow-
through of the fourth run; 5) pooled protein containing fractions; 6) pooled
protein containing fractions after desalting; 7) murine serum control; 8) fetuin-
B deficient serum.
The pooled fetuin-B fractions were dialyzed in PBS overnight. The con-
centration of the purified fetuin-B was determined at 0.32 mg/ml by OD280
measurement in comparison to a bovine fetuin-A standard.
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Sequencing the Recombinant Fetuin-B Protein
Secreted proteins have a short N-terminal sequence, the leader sequence or
signal peptide, that mediates the passage through the cell membrane. During
the passage through the ER-Golgi compartment the signal peptide is cleaved
by an enzyme, the signal peptidase, which implies that the secreted protein
begins with a different N-terminus.
By computer analysis a potential signal peptide was identified at the N-
terminus of the primary fetuin-B amino acid (AS) sequence. The signal
peptide was predicted to encompass residues 1-18 according to the ExPASy
database, UniProtKB/Swiss-Prot entry Q9QXC1 (http://au.expasy.org/
uniprot/Q9QXC1). To identify the N-terminus of the secreted fetuin-B pro-
tein the purified fetuin-B fusion protein was sequenced. The N-terminal se-
quence was determined as arginine (Arg), serine (Ser), proline (Pro), proline
(Pro) and alanine (Ala). This result experimentally confirmed the predicted
signal peptide of the first 18 AS. The complete AS sequence is shown in
Figure 3.29.
In addition peptide mass fingerprints derived from mass spectroscopy of
the purified protein unequivocally proved the identity of the recombinant
protein as mouse fetuin-B.
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3.3.4 Precipitation Inhibition Assay
Fetuin-A is a potent inhibitor of calcification. The calcium phosphate pre-
cipitation inhibition assay is a well established in vitro method to study the
effect of fetuin-A on precipitation of calcium phosphate from a saturated
calcium phosphate solution [63, 11]. Since fetuin-B is the closest relative of
fetuin-A, it was analyzed if fetuin-B could also inhibit the precipitation of
calcium phosphate in vitro. The first assay was performed by measuring the
amount of calcium and phosphate precipitate in the presence of 1-5 % fetuin-
B deficient serum, comparing its effect to wildtype and fetuin-A-deficient
serum and a protein-free solution as negative control. Figure3.33 A shows
that under the conditions of the assay wildtype and fetuin-B-deficient serum
effected full precipitation when admixed at 1% to the precipitation mixture.
In contrast fetuin-A deficient serum had to be admixed at a minimum of 3%
[vol/vol] to effect a similar inhibition. Thus fetuin-B unlike fetuin-A is not an
efficient inhibitor of calcium phosphate precipitation. Purified recombinant
mouse fetuin-B likewise failed to inhibit the precipitation of calcium phos-
phate (Figure 3.33 B), confirming the result obtained with fetuin-deficient
sera and with recombinant fetuin-B expressed in bacteria [11, 15].
3.3.5 TGF-β Reporter Activity in Mink Lung Cells
Fetuin-A has been shown to modulate TGF-β activity by acting as a soluble
TGF-β type II receptor mimic [12]. Fetuin-B revealed sequence homology
with the TGF-β type II receptor as described in subsection 1.1.1 (Figure
1.2). Therefore, the interaction of fetuin-B and TGF-β was analyzed in a
biological system: the mink lung cell reporter assay.
The mink lung cell reporter assay is based on a stably transfected reporter
construct that consists of a PAI-1 promoter and a luciferase gene in mink
lung epithelial cells (MLEC). The PAI-1 gene is directly activated by TGF-β
signaling, therefore, the presence of the PAI-1 promoter makes the mink lung
cells TGF-β responsive, with a readout of luciferase activity. Additionally,
the expression of luciferase depends on the concentration of TGF-β: the more
TGF-β, the more luciferase activity is measurable (Figure 3.34A)[64].
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Figure 3.33: Calcium phosphate precipitation inhibition assay. (A) The as-
say was performed using wildtype, fetuin-A-deficient (fetuin-A -/-) and fetuin-
B-deficient (fetuin-B -/-) sera. Wildtype and fetuin-B-deficient sera inhibited
precipitation at low serum concentrations. Fetuin-A-deficient sera show a re-
duced inhibition capacity. (B) The assay was performed using bovine fetuin-A
and recombinant murine fetuin-B expressed in COS-7 cells. In both cases 100
% precipitation was determined by the protein-free control. Pure fetuin-A
inhibited precipitation of calcium phosphate, whereas, pure fetuin-B did not
show any inhibitory potential.
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Figure 3.34: Luciferase activity of mink lung (MLEC) reporter cells. (A)
Increasing amounts of TGF-β led to increased luciferase expression; (B) in-
creasing amounts of bovine fetuin-A did not induce luciferase expression in the
absence of TGF-β while increasing amounts of fetuin-B did induce luciferase
expression in the absence of TGF-β. The addition of 250 pg/ml TGF-β to
the increasing amounts of fetuin-A and fetuin-B caused luciferase expression
in an additive manner. LCPS: luciferase counts per sec.
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The assay was performed employing a fixed TGF-β concentration of 250
pg/ml. Recombinant murine fetuin-B fusion protein and bovine fetuin-A
were added in increasing concentrations. Figure 3.34 B shows the impact of
fetuin-B and fetuin-A on TGF-β signaling.
Fetuin-B induced luciferase activity in the absence of TGF-β in a concen-
tration dependent manner. whereas, fetuin-A did not induce any luciferase
activity.
In the presence of 250 pg/ml TGF-β again luciferase activity was further
increased with increasing concentrations of fetuin-B. In contrast, the baseline
luciferase activity of 250 pg/ml TGF-β was not further increased by adding
increased amounts of fetuin-A.
Thus, fetuin-B induced the luciferase expression, controlled by the PAI-
1 promoter but did not inhibit TGF-β activity. The inhibitory activity of
fetuin-A, which was previously shown in this assay for recombinant human
fetuin-A, could not be reproduced with bovine fetuin-A for unknown reasons.
3.3.6 Serum Concentration of Fetuin-B
Mouse fetuin-B serum levels had been previously estimated employing a
prokaryotically expressed MBP-fetuin-B fusion protein [15]. Here, these mea-
surements were repeated employing the eukaryotically expressed fetuin-B
protein as a standard.
Quantitative fetuin-B Western blots were performed in order to estimate
the fetuin-B level in mouse serum. Nine adult females and ten adult male
mice were analyzed. As shown in Figure 3.35 the average serum concentration
of fetuin-B in adult mice was higher in males (406 µg/ml ± 41 ) than females
(334 µg/ml ± 93). This is in contrast to the fetuin-B serum levels reported
previously in human serum [15] where females had 50% higher serum levels
than males. However, in this analysis females showed a broader fetuin-B
concentration range, indicating that the concentration may cycle. This needs
further investigation.
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Figure 3.35: Fetuin-B serum concentration in adult mice. (A) Represen-
tative Western blot of adult mouse serum (6-10) and recombinant-fetuin-B
dilution series (1-5) that were quantified by the ImageJ software in (B) The
median fetuin-B serum concentration in males was 0.4 mg/ml ± 41 (n=11).
The median serum concentration in females was 0.3 mg/ml ± 93 (n=9).
3.3.7 Summarizing the Results of the in Vitro Data
The fetuin-B cDNA controlled by a constitutively active CMV promoter
and elongated by a histidine purification tag was successfully cloned into
an adenoviral vector system. The recombinant fetuin-B fusion protein was
purified from the cell culture supernatant of transfected COS-7 cells. The N-
terminus of the mature fusion protein was sequenced. Thereby, the predicted
signal peptide was confirmed experimentally.
Employing the purified recombinant fetuin-B protein as a standard the
concentration of fetuin-B in mouse serum was assessed by Western blot anal-
3.4. PROMOTER ANALYSIS 95
ysis. The average serum concentration was determined at 0.4 mg/ml for
males and 0.3 mg/ml for females. The purified fetuin-B protein did not
reveal any calcium phosphate precipitation inhibitory potential unlike it’s
closest relative fetuin-A, which is known as a strong inhibitor of calcium
phosphate precipitation.
Unlike fetuin-A, fetuin-B activated luciferase expression in the mink lung
cell reporter assay in the absence of TGF-β. Still further experiments need
to elucidate whether the luciferase expression was due to fetuin-B mediated
signaling via the TGF-β pathway or whether other mediators were contained
in the fetuin-B fraction as a viral contaminant.
3.4 Promoter Analysis
3.4.1 Cloning and Analysis of the Fetub Promoter
The promoter controlling Fetub expression has not been studied yet. Com-
puter analysis predicted two possible promoter regions for the murine Fetub
gene as shown in Figure 3.36 and one putative promoter region was found
for human and rat gene.
Figure 3.36: Localization of the two predicted FetuB Promoters. The FetuB
gene’s exon/intron structure and the localization of the predicted promoter
regions are illustrated in this figure. Each promoter region (red box) is located
upstream from each alternative 5’-UTR (for review see Section 1.1.3). MP1:
potential mouse promoter #1; MP2: potential mouse promoter #2.
To construct a Fetub reporter assay the two predicted murine promoter
regions were amplified by PCR and cloned into a pEGFP-1 vector (BD Bio-
sciences Clonetech) as shown in Figure 3.37.
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Figure 3.37: Murine fetuin-B promoter constructs. 600 bp of the predicted
mouse promoter #1 and #2 were cloned into the promoter less vector pEGFP-
1. The pEGFP-1 vector contains the enhanced green fluorescence protein
(EGFP) gene that is only expressed in the presence of an active promoter.
The promoter activity can be assayed by transfecting the recombinant vector
into target cells and screen for green fluorescing cells.
The reporter constructs were transfected into various cell types (HeLa,
3T3, HaCaT, Hepa1-6 and HepG2), to study Fetub expression in varying
cellular contexts.
The putative promoter sequence MP1 that is located more distal to the
Fetub gene led to the expression of EGFP in all tested cell types, whereas,
the putative promoter sequence MP2 that is located more proximal to the
Fetub gene did not lead to EGFP expression, when compared to the negative
control. This indicates that MP2 is either not functional as a promoter, or
that MP2 functions tissue specific, e.g. for the ovary.
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Figure 3.38: Murine fetuin-B promoter analysis. Two putative fetuin-B
promoter regions (MP1 and MP2) were cloned into a EGFP-reporter vector
and transfected into the murine and human cell lines indicated on top of
the figure. A CMV promoter was used as a constitutive active promoter.
The negative control (NC) was a EGFP-reporter vector without a promoter.
HeLa: human cervix carcinoma cell line; 3T3: murine fibroblast cell line;
HaCaT: human epithelial keratinocyte cell line; Hepa1-6: murine hepatoma
cells; HepG2: human hepatoma cells.

Chapter 4
Discussion
4.1 Generation of Fetuin-B-deficient Mice
4.1.1 Gene Deletion
The fetuin-B-gene knockout was achieved by deleting exon 2 and 3 and in-
serting a neomycin resistance marker of E. coli origin (neo-cassette). The
overall genomic sequence of the fetuin-B gene was thus shortened by 235
bases.
The reason for deleting exon 2 and 3 was that two alternative transla-
tion start codons were described for the Fetub gene located in these exons.
By deleting these exons the translation start codons, required for protein
synthesis were removed, regardless of the putative splice variants of primary
transcripts.
The deletion of exon 2 and 3 was sufficient to prevent the translation of
fetuin-B. This was proven on the protein level: fetuin-B was absent in the
serum and tissue of fetuin-B-mutant mice.
4.1.2 Embryonic Stem Cells and Genetic Background
The injection of ES cells directly into the cavities of blastocysts is a straight-
forward method to generate chimeric mice carrying alleles with a mutant
genome [70]. To derive a mutant mouse strain from these chimeric mice,
germ-line transmission has to be achieved. This is known to depend heav-
ily on the genetic background of the manipulated ES cells and the recipient
blastocyst. For example, Balb/c blastocysts have been shown to work well in
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combination with C57BL/6-derived ES cells [71], and the use of F1 hybrid ES
cells have demonstrated a superior developmental potential [72]. However,
the advantage of the superior developmental potential of F1 hybrid stem cells
is diminished by the disadvantage of obtaining a mutant mouse strain with a
mixed genetic background. As a consequence a series of backcrossings with
an inbred strain is required to ensure a uniform genetic background. Accord-
ingly, in this work F1 hybrid ES cells (129/Sv x C57BL/6) and inbred ES
cells (C57BL/6) were targeted and subsequently injected into Balb/c-derived
blastocysts in parallel. Their transfection and homologous-recombination
rate were identical. However, as described above, the F1 hybrid stem cell
was superior to the inbred ES cell because it transmitted the germ-line. As a
result, the targeted mutation was obtained on a mixed genetic background.
This required time-consuming backcrossing with the inbred strain C57BL/6.
At least 10 generations of backcrossing, three months per generation, are re-
quired to obtain a uniform genetic background consisting of 99.9% identical
genetic loci.
The characterization of the fetuin-B-deficient mouse strain was begun on
F2 littermates after the fifth backcrossing generation with the C57BL/6 in-
bred strain. Statistically 98% of the donor genome was eliminated by that
time. Thus, wildtype littermates and not commercial pure-bred wildtype
animals were used as control animals. Some of the differences, such as the
clinical chemistry values, for example, could thus be due to the remaining
genetic divergence among the individuals.
4.1.3 Screening Procedure
After the transfection of the ES cells it was necessary to identify the homol-
ogously recombined ES-cell clones. For the first screening, a PCR approach
was chosen because it facilitates fast and high-throughput screening com-
pared to Southern bloting. However, the PCR absolutely requires a positive
control. To this end a positive control was cloned: the knockout control
vector. It resembled the gene-targeting vector but consisted of an extended
3’-homologous sequence, thereby mimicking the recombinant fetuin-B allele.
The knockout control vector enabled simulation of the PCR screening proce-
dure, thus improving performance and enshuring the reliability of the screen-
ing system.
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Southern blot analyses were performed to confirm the PCR-positive clones,
again facilitated by the use of the knockout control vector as a positive con-
trol. Both analytic procedures were optimized before the targeted ES cell
DNA was analyzed. Therefore, it can be safely assumed that all positive
ES-cell clones were detected by the screening procedure.
4.1.4 Expression of Fetuin Family Proteins
The fetuin-B-null mutation was confirmed on the level of protein expression
using Western blot analysis of serum. The absence of the fetuin-B protein was
determined in the serum of homozygous fetuin-B-deficient mice and half the
normal amount of fetuin-B protein was determined in the blood of heterozy-
gous mice. This finding suggests that both Fetub alleles are independently
expressed under physiological conditions.
It is known that the fetuin-B protein is less abundant in fetuin-A-deficient
mice [15]. This was determined not only on the protein level, but also on
the level of mRNA expression (unpublished data). The down-regulation of
fetuin-B in fetuin-A-deficient mice might be caused by regulatory sequences
that were compromised in the course of targeting the fetuin-A gene, since
both genes are located in close proximity. Vice versa fetuin-A expression
may be compromised in fetuin-B-knockout mice. Thus, the level of fetuin-A
protein expression was analyzed in the serum of fetuin-B-deficient mice. The
expression of fetuin-A was unchanged in both heterozygous and homozygous
fetuin-B-deficient mice. This suggests that the expression of the fetuin-A
gene was not compromised by targeting the fetuin-B gene and that the ex-
pression of fetuin-A does not depend on the availability of fetuin-B.
4.1.5 Fetuin Serum Concentrations
The serum concentration of fetuin-A in adult mice was measured at about
200 µg/ml [13]. Denecke et al. first quantified fetuin-B within mouse serum
[15]. They used prokaryotically expressed MGP-fetuin-B fusion protein as a
reference protein and determined 156 ± 3 µg/ml fetuin-B within the serum
of male mice. Furthermore, they detected that fetuin-B levels are two-fold
higher in human females than in males.
In this study, eukaryotically expressed instead of bacterially expressed
fetuin-B was employed as a standard. Adult male and female mice were
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analyzed. The overall fetuin-B concentration measured in this study was
higher than determined by Denecke et al. (156 µg/ml compared to 406
µg/ml for males and 334 µg/ml for females) and also higher than the known
concentration for fetuin-A. However, in mice the concentration of fetuin-A is
known to be highest after birth [25].
This study showed that females show a wider range of serum concentration
of fetuin-B when compared to males, implying that fetuin-B could undergo a
cyclic regulation in females, possibly following the estrus. To this end further
studies need to evaluate whether there is a link between the estrus phase and
the serum concentration of fetuin-B.
4.2 Phenotyping
4.2.1 Vitality
The segregation analysis showed that 25% of the F2 offspring were wildtype,
48% were heterozygous and 28% were fetuin-B deficient. This data conforms
to Mendel’s second law, predicting 25% wildtype, 50% heterozygous and 25%
fetuin-B deficient mice.
Firstly, this data showed that fetuin-B-deficient mice are vital. Secondly,
they indicated that fetuin-B-deficient mice develop without extraordinary
embryonal lethality, since fetuin-B-deficient mice are born at the same rate
as their wildtype littermates. Hence, embryo development is independent of
embryonic expression of fetuin-B. However, fetuin-B may still be required for
proper embryo development since it may be provided by the mother through
the placenta. A hint in that direction stemmed from the observation that
fetuin-B-deficient females were not able to conceive. Embryo development
did not even begin in these mice, as detailed in the following section.
4.2.2 Female Infertility
This work revealed that fetuin-B-deficient females were infertile while het-
erozygous females were fertile. Fetuin-B-deficient females did not deliver
when mated with any genotype. Copulation activity was normal as vaginal
plugs were routinely observed after mating. By the same token, no differ-
ences between the copulation activity of wildtype and fetuin-B deficient male
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mice were observed. Furthermore, it was shown that fetuin-B-deficient males
were able to sire offspring when mated to wildtype and heterozygous females.
In conclusion, it was shown that fetuin-B was necessary for female but not
for male reproduction.
The fact that the targeted deletion of a serum protein that is predomi-
nantly expressed by the liver resulted in infertility seems surprising. However,
proteins of the extracellular coat surrounding non-cyprinoid fish oocytes are
also synthesized by the liver. They are transported by the bloodstream to the
ovary where they are incorporated into the vitelline envelope of the growing
oocyte. The proteins involved in the vitelline envelope and the mouse zona
pellucida are closely related to each other, sharing 25% sequence identity
between trout and mouse [73]. Also avian eggs consist of some proteins that
are partly synthesized by the liver and others in the ovary [74]. It would
appear that during evolution the sites of synthesis included the liver and the
ovary.
Additionally, the targeted deletion of the serum protein urinary trypsin
inhibitor/bikunin that is expressed by the liver resulted in impaired fe-
male fertility. This was due to reduced numbers of ovulated oocytes and
an unstable cumulus oocyte complex, COC [75, 76]. However, bikunin is
the only proteinase inhibitor that has been shown to contribute to female
fertility so far according to the mouse genome informatics database, MGI
(www.informatics.jax.org).
In fact, the MGI database lists 216 targeted genes that contribute to fe-
male infertility. These mouse models reveal defects in germ cell maintenance,
proliferation and development as in Dazla-deficient mice [77], the formation of
primordial follicles as in Figα-deficient mice [78], the formation of secondary
follicles as in Gdf9-deficient mice [79], the formation of antral follicles as in
FSHβ-deficient mice [80], ovulation problems such as in cyclooxygenase 2 [81]
and progesterone receptor deficiencies [82], fertilization problems such as in
CD9-deficient mice [52, 50], oocyte-to-embryo transition deficiencies such as
in Zar1-deficient mice [36] or implantation failures as in Lif deficient mice
[83].
Fetuin-B-deficient females were able to ovulate and histological sections of
the ovaries revealed different stages of folliculogenesis as expected for fertile
mice. This implies that signaling mediated by the follicle-stimulating hor-
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mone and by the luteinizing hormone in the ovarian follicle was not affected
in the fetuin-B-deficient mice.
The early folliculogenesis was not influenced by the absence of fetuin-
B, as questioned in a recent study on newborn mouse ovaries: Choi et al.
showed that fetuin-B was expressed during early oogenesis. Interestingly,
its expression was significantly down-regulated in ovaries that lacked Nobox,
a transcription factor for oocyte-specific genes. Nobox -knockout ovaries are
grossly normal at birth, however, the lack of Nobox inhibits oocyte and fol-
licle growth beyond the primordial follicle stage [84]. The fetuin-B-deficient
mouse model showed that even though fetuin-B was down-regulated in the
Nobox deficient oocytes it did not contribute to the observed phenotype be-
cause the early folliculogenesis is not altered in the fetuin-B-deficient mice.
However, the down-regulation of fetuin-B in the absence of Nobox suggests
that Nobox might regulate the oocyte-specific expression of fetuin-B possibly
by activating the promoter MP2 (characterized in Section 3.4.1).
The ovulated oocytes of fetuin-B-deficient females were well-organized in
cumulus-oocyte complexes (COC). These complexes have been shown to be
essential not only for the development of the oocyte but also for the fertil-
ization potential of the oocytes.
However, the ovulated oocytes of naturally mated fetuin-B-deficient fe-
males did not develop to the two-cell stage. Morphologically, these oocytes
did not reveal any of the characteristics of fertilized oocytes such as two
polar bodies and pro-nuclei, furthermore, their zona-pellucida thickness was
reduced and a perivitelline space was never observed.
The morphological phenotype described above implies that the infertil-
ity of fetuin-B-deficient females was most likely due to a fertilization defect
and not to a blocked oocyte-to-embryo transition as in mice deficient in the
Zar1 (Zygote arrest1, maternal-effect gene) and Zfp36I2 (zinc-finger protein
involved in mRNA degradation) [36, 85]. The fetuin-B deficiency must have
come into account somewhere between the sperm’s capacitation, penetra-
tion through the cumulus mass, the zona pellucida and the oocyte’s plasma
membrane, which is essential for fertilization.
In this respect, oviductal glycoproteins have been shown to bind to the
zona pellucida of oocytes [86] and contribute to heightened fertilization [87].
Furthermore, they have been reported to enhance sperm capacitation, bind-
ing to the zona pellucida and to facilitate sperm penetration [88], possibly
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by influencing the time course of acrosomal enzyme secretion or degradation
[89]. Hunter et al. stressed the impact of glycoproteins on the viscosity of
the luminal fluid that stabilizes the micro-environments surrounding sperm,
oocyte and embryo [90]. However, the deletion of oviduct-specific glycopro-
tein (OGP) did not affect female fertility [91].
Mouse models revealed that the deletion of the zona pellucida proteins
ZP3 and ZP2 was associated with female infertility due to impaired follicu-
logenesis, cumulus-oocyte-complex formation and the ovulation of reduced
numbers of zona-free oocytes that were not fertilized [92]. However, Wassar-
man et al. were able to show that mice heterozygous for the ZP3 deficiency
reproduced normally despite a reduced zona pellucida thickness. Hence the
thickness of the zona pellucida is not of major importance per se [93].
In vitro, fetuin-A inhibited the conversion of ZP2 to ZP2f , a process that
causes zona pellucida hardening during spontaneous murine oocyte matura-
tion [94]. Furthermore, fetuin-A inhibited the conversion of ZP3. ZP3 binds
sperm and triggers the acrosome reaction that is essential for fertilization.
ZP3 conversion causes the loss of this ability [95]. The conversion of ZP2 and
ZP3 results in a block to polyspermy. Another study of Kalab et al. revealed
that human follicular fluid inhibited ZP2 conversion in murine oocytes in
vitro. Purified human fetuin-A was able to substitute for the follicular fluid.
However, the inhibitory potential of the follicular fluid was not altered after
immuno-depletion of fetuin-A. Thus other inhibitory molecules are likely to
be present in the follicular fluid [96]. This result is supported by the phe-
notype of fetuin-A-deficient mice, which do not reveal reproductive defects.
Considering the clear phenotype of fetuin-B-deficient female mice, fetuin-B
not fetuin-A might be a key player in preventing zona pellucida hardening.
Fetuin-B was never studied or monitored in any of these studies and it is well
possible that it was present in the fetuin-A preparations as a contaminant.
The significance of the perivitelline space was revealed by Motosugi et
al. in a study on oocyte polarity. These authors reported sperm swimming
around the perivitelline space, possibly for further capacitation, before bind-
ing to the plasma membrane. The experimental enlargement of the periv-
itelline space in the non-polar body half increased the regional probability
of fertilization. Based on these experiments, the authors proposed a model
in which the space asymmetry exerted by the first polar body and the zona
pellucida directs sperm entry preferentially to the polar body half, with no
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need for oocyte polarity [97]. Possibly, the simple contact between sperm
head and oocyte surface is not sufficient and some free space is required to
trigger the fusion of sperm and oocyte.
The molecular basis of sperm-oocyte fusion is still poorly understood.
However, there are several animal models that reveal a fertilization blockade
due to impaired sperm and oocyte fusion e.g. glycosylphosphatidylinositol-
anchored proteins (GPI-APs) on the oocyte’s surface [98]. The oocyte spe-
cific deletion of the Pig-a gene, encoding an enzyme involved in GPI anchor
biosynthesis, demonstrated that at least one GPI-anchored protein is essen-
tial for the fusion of sperm and oocyte [99]. Furthermore, the deficiency
of CD9, a transmembrane protein involved in cell migration and adhesion
[100] that is expressed on oocytes, was also shown to lead to impaired sperm
oocyte fusion [52, 50, 51], whereas the deletion of CD81 that associates with
CD9 on the cell surface showed reduced sperm oocyte fusion.
The exact mechanism leading to infertility in fetuin-B-deficient mice re-
mains to be determined. Furthermore, it is still unknown, whether fetuin-B
contributes to fertility as a structural, or as a catalytic protein. Members of
the cystatin superfamily are known to be cysteine-protease inhibitors. More-
over, fetuin-A was shown to inhibit zona pellucida hardening by preventing
the proteolytic cleavage of the zona pellucida proteins during in vitro matu-
ration. Therefore, it is likely that the physiological role of fetuin-B is of an
inhibitory nature. At this point it may be mentioned it has also been sug-
gested that fetuin-B may be involved in the metastatic potential of tumors
as a tumor suppressor [18]. To draw a parallel to the potential interaction
of fetuin-B with the extracellular matrix of the oocyte, this might be due to
the interaction of fetuin-B with the extracellular matrix of the tumor cells.
A third possibility is that fetuin-B as a serum protein could be involved in
transporting factors to the oocyte that are essential for fertility. Further
studies are required to elucidate the molecular role of fetuin-B in oocyte
fertilization.
4.2.3 Anatomy and Morphology
Fetuin-B-deficient mice were first studied by non-invasive techniques such as
morphological analysis according to Fuchs et al. [101] and X-ray analysis.
Morphological analysis acquires first-line information about skeletal mal-
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formations such as developmental patterning defects, metabolic defects, growth
defects, modeling and remodeling defects, and aging and immune system de-
fects [101]. Visible parameters like an abnormal gait, positioning of the
limbs, or abnormal struggling, for example, would have been indicators for
the conditions mentioned above.
Radiography is a powerful technique for visualizing skeletal diseases. In
order not to miss any skeletal phenotypes radiographs of 12 month old mice
were taken using X-rays. Neither morphological nor X-ray analysis revealed
any major disorders.
Necropsy of the mice and subsequent histological examination of their
tissue was an invasive method of searching for alterations associated with
the deletion of fetuin-B. These methods revealed that the gross anatomy of
the body, the organs, and the cellular morphology were virtually identical in
wildtype and fetuin-B-deficient mice.
In summary, the fetuin-B deficiency did not affect the anatomy or the
macro and micro morphology. In particular, fetuin-B deficiency was not
associated with cellular infiltrations suggesting infections or tumorigenesis.
This latter point was questioned when fetuin-B was suggested to be a tumor
suppressor in the literature [18]. It was thought to be involved in malign
tumor progression. This is consistent with the finding that fetuin-B-deficient
mice did not show spontaneous tumor formation. However, fetuin-B-deficient
mice are an ideal tool for clarifying the role of fetuin-B as a tumor suppressor
in an induced tumor system as has been the case in fetuin-A deficient mice
[30, 31, 32].
4.2.4 Physiology and Learning
Physiological parameters were analyzed to further characterize the fetuin-
B-deficient mice. To investigate manifestations of metabolic malfunctions,
the weight gain of maturing fetuin-B-deficient mice and their wildtype litter-
mates was recorded. However, no significant differences in the weight gain of
sex- and age-matched fetuin-B-deficient and wildtype mice were discovered.
Furthermore, the weight of the animals was fully consistent with the data
provided by the mouse phenome database (www.phenome.jax.org).
In addition, glucose tolerance tests were performed, because initial serum
analysis had revealed irregular glucose levels in male fetuin-B-deficient mice
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of the original mixed genetic background, indicating a glucose intolerance.
Furthermore, fetuin-A is thought to be involved in glucose metabolism [68,
28, 29]. Glucose intolerance can be due to a deficiency in insulin production
and secretion (type 1), or insulin resistance (type 2) when supra-physiological
concentrations of insulin are required to achieve physiological effects.
Fetuin-B-deficient mice of the fifth C57BL/6 backcrossing generation did
not reveal an altered glucose tolerance when compared to their wildtype
littermates. Possibly, the recorded irregular glucose levels were due to the
genetic variation of the analyzed littermates: C57BL/6J mice are known to
be more glucose intolerant than other mouse strains, e.g. 129/Sv mice (data
provided by mouse phenome database). Since the fetuin-B-deficient mice
were derived from a 129/Sv x C57BL/6 hybrid, it seems plausible that these
genetic traits segregated among the littermates.
Heart rate and blood pressure give insight into the condition of the cardio-
vascular system. The measurement of blood pressure and heart rate at the
age of 12 weeks showed no significant differences between fetuin-B-deficient
mice and their wildtype littermates. This first screening implies that there is
probably no cardiovascular disease to be expected in adult fetuin-B-deficient
mice.
As described in section 2.3.8 the blood pressure measurement method
required a training period to adapt the animals to the procedure. The begin-
ning of the training phase was characterized by unmeasurable blood pressure
and heart rate values, since the animals were too excited about being re-
strained. As a side effect of the measurements, a learning effect became
obvious, expressed by the reduction of blood pressure and pulse rate. Both
genotypes adapted equally well to the measurement procedure. This also
indicates that the learning ability of the fetuin-B-deficient mice was not al-
tered.
Taken together, the physiological parameters analyzed in this study, such
as weight, glucose tolerance, blood pressure and heart rate did not depend
on the availability of fetuin-B.
4.2.5 Clinical Chemistry Screening
The clinical blood screen is a very powerful tool for detecting changes in
various organ systems, metabolic pathways and the blood coagulation cas-
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cade. The diagnostic impact of clinical chemical parameters for pathological
conditions is well described [102] and parameter-value changes can easily be
linked to clinical conditions.
The clinical chemistry screening in fetuin-B-deficient mice did not reveal
any manifestations of pathophysiological conditions. The parameter values
determined were within the average of the control group. Again, minor dif-
ferences did not reach statistical significance and might have been due to
the small animal numbers that were analyzed or the variable genetic back-
ground of theses animals. In support of the other testing carried out, no signs
of changes in major organ systems, metabolic pathways or the coagulation
system were detectable in the fetuin-B deficient mice.
4.3 Recombinant Murine Fetuin-B
4.3.1 Eukaryotic Expression of Recombinant Fetuin-B
Up to now, murine fetuin-B is not commercially available. In the course of
this thesis, murine fetuin-B was expressed in eukaryotic cells, COS-7. Previ-
ously, recombinant fetuin-B had been expressed in a prokaryotic system [15].
However, the eukaryotic-expression system has several advantages including
the eukaryotic specific glycosylation of fetuin-B, which is absent in prokary-
otes. With regard to the use of the recombinant glycoprotein fetuin-B in
functional in vitro assays, the choice of the eukaryotic expression system was
of major importance.
Another advantage of the eukaryotic expression system was that it en-
abled the secretion of the expressed fetuin-B protein. This was promoted
by its endogenous signal peptide. Hence, the eukaryotic cells secreted the
protein into the cell culture media, from which, subsequently, fetuin-B was
purified. In comparison, the prokaryotic expression of fetuin-B had led to
inclusion bodies which had to be lysed under denaturing conditions. After
that, the proteins included had to be renatured. In summary, the expression
of fetuin-B in eukaryotic cells yielded a much more native fetuin-B than from
prokaryotic cells.
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4.3.2 Fetuin-B Transfecting Adenovirus
There are various ways of transfecting cultured eukaryotic cells. Depending
on cell type and the intended transfection efficiency, the method of choice
may include lipofection, electroporation and viral transfection [62]. The ad-
vantage of viral transfection is that it leads to a homogeneously transfected
cell population, due to receptor-mediated internalization of the virions. Ad-
ditionally, a large number of virions deliver the recombinant DNA into one
cell, thereby ensuring its rapid and plentiful expression. Furthermore the
viruses may eventually be utilized in whole animal experiments to study the
effect of fetuin-B over-expression in vivo. And lastly, it should be possible to
rescue the phenotype of fetuin-B deficiency in vivo by adenoviral transfection
of fetuin-B.
4.3.3 Inhibition of Ectopic Calcification
Fetuin-A has been unequivocally identified as a potent inhibitor of ectopic
mineralization using gene-knockout technology in mice [25, 24]. This pheno-
type had confirmed the results of the previously developed in vitro assay re-
vealing that fetuin-A is a potent inhibitor of calcium phosphate precipitation
in vitro [63, 11]. In the assay, fetuin-A inhibits the precipitation of calcium
phosphate. Accordingly, fetuin-A-deficient serum has a reduced capacity
to inhibit precipitation compared to serum containing fetuin-A. Fetuin-A-
deficient serum has to be employed in higher concentrations to reach the
inhibitory potential of wildtype serum. This indicates that there are addi-
tional factors taking over the function of fetuin-A but evidently these are
less effective. The question was whether fetuin-B was one of these factors.
In order to analyze whether fetuin-A and fetuin-B had similar functions,
fetuin-B-deficient serum was assayed for its potential to inhibit calcium and
phosphate precipitation in vitro. Conversely, fetuin-B-deficient serum was
able to inhibit calcium and phosphate precipitation in the in vitro assay. It
did not differ from the inhibition potential of wildtype serum. Obviously,
the effect of fetuin-A in the fetuin-B-deficient serum over-ruled the lack of
fetuin-B. Therefore the assay was repeated with the purified recombinant,
glycosylated fetuin-B. Still, fetuin-B did not show any inhibition potential at
all. This is consistent with the finding that prokaryotically expressed fetuin-B
was not able to inhibit calcium and phosphate precipitation in vitro either.
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Moreover, the radiographs of 12-month-old fetuin-B-deficient mice did not
reveal any signs of a calcification phenotype in vivo. Furthermore, the clinical
chemistry screening did not give any evidence for interference in organical
functions due to calcification. Still, these analysis have to be repeated for a
DBA/2 strain deficient in fetuin-B since fetuin-A-deficient mice reveal ectopic
calcification depending on the genetic background, again implying a multi-
factorial predetermination. However, the results given above suggest that
fetuin-B is not one of these factors.
4.3.4 TGF-β Biology
TGF-β signaling was studied because there is a short amino acid sequence
within the primary protein structure of fetuin-A that is homologous to the
TGF-β receptor type II. This homology was also found within the primary
structure of fetuin-B as detailed in the introduction. Unpublished data of
Westenfeld et al. showed that human fetuin-A interacts with TGF-β, thereby
reducing TGF-β signaling in mink lung epithelia cells that were stably trans-
fected with a PAI-1/luciferase reporter system. However, the interaction
of human fetuin-A with TGF-β could not be reproduced employing bovine
fetuin-A in this study. Bovine fetuin-A was unable to activate the PAI-1
promoter, and additionally, did not alter TGF-β signaling. On the contrary,
fetuin-B was able to activate the PAI-1 promoter and further enhanced the
signaling in combination with TGF-β.
Fetuin-B’s activation of the PAI-1 promoter may have several reasons:
firstly, fetuin-B could directly activate signaling pathways that lead to PAI-
1 expression. Secondly, fetuin-B may have stimulated the endogenous ex-
pression of TGF-β that then activated the PAI-1 promoter in an autocrine
fashion. This kind of stimulation would involve de novo protein synthesis
and would be time dependent. Therefore it could be constrained by shorter
assay times or the inhibition of protein synthesis. Thirdly, either TGF-β
or other substances that can already cause the activation of PAI-1 in low
amounts may have contaminated the purified fetuin-B preparations. This
is a known problem in virus-derived proteins. To exclude this possibility,
fetuin-B should be expressed in a virus-free system.
Thus, a direct answer as to whether fetuin-B interacts with TGF-β ex
112 CHAPTER 4. DISCUSSION
vivo could not be given by this experiment and more refined experiments are
required to clarify this point.
4.4 Outlook
The infertility of the fetuin-B-deficient mice opens a novel research field for
fetuins. This work describes a novel target for the investigation of idiopathic
sterility and for birth control.
The future aim will be to elucidate the molecular mechanism in which
fetuin-B is involved in successful reproduction. In this respect, in vitro fer-
tilization (IVF) studies will provide information regarding the sperm’s ca-
pacitation potential that might be reduced in vivo in mice lacking fetuin-B.
Furthermore, by removing the zona pellucida, IVF studies will be able to
elucidate the contribution of the ZP to the fertilization defect.
If IVF studies fail, further intracytoplasmic sperm injection (ICSI) will
provide information about the developmental potential of fetuin-B-deficient
oocytes.
Later stages of pregnancy may also be affected by fetuin-B deficiency.
Thus, embryo-implantation studies are planned to demonstrate whether ma-
ternal fetuin-B is essential for later stages of pregnancy, such as implantation
and the maintenance of pregnancy.
Summary
This study aimed at elucidating the physiological function of fetuin-B. For the
first time, the serum protein fetuin-B was deleted in an animal model. This
was achieved by gene targeting in embryonic stem cells. The analysis of the
fetuin-B-deficient mice revealed that fetuin-B was essential for fertilization.
Female fetuin-B-deficient mice failed to produce any offspring when mated
with any genotype. Heterozygous fetuin-B-deficient female mice and males of
any genotype were reproductive, however. The main finding of this study was
that oocytes derived from naturally mated fetuin-B-deficient female mice did
not reveal any fertilization characteristics and did not develop to two-cell pre-
implantation embryos in vitro, indicating a fertilization defect. It remains
to be clarified whether fetuin-B is required as a structural, a catalytic, or
a transport protein. Regardless of the exact mechanism, a novel target for
fertilization control was identified: fetuin-B.
Further characterization of the fetuin-B-deficient mice did not reveal any
abnormalities with regard to their anatomy, morphology, physiological pa-
rameters or metabolic functions. It remains to be studied if the fetuin-B-
deficient mice develop disease when challenged or stressed. For example, the
hypothesis that fetuin-B may function as a tumor suppressor preventing tu-
mor progression could ideally be studied in an induced-tumor model using
fetuin-B-deficient mice.
Functional in vitro assays performed with purified recombinant fetuin-
B showed that it did not compensate for fetuin-A deficiency, as shown by
their distinct calcium phosphate precipitation inhibiting potential. As for the
fetuin-A- and fetuin-B-deficient animal models, both exhibit distinct pheno-
types and differ completely in their most prominent phenotypes: fetuin-A
deficiency leads to ectopic calcification, while fetuin-B deficiency leads to fe-
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male infertility. The data provided by this study thus clearly suggests that
the fetuin-family members have distinct functions in vivo.
Appendix
Pedigrees
1.1 SPF
12.09.05
5f -
1/2D2(FetA-/-) x 3+/-
(17.08.05 - 19.12.05) 
1.3 SPF
15.10.05
2f 4m
1.2 SPF
19.09.05
4f 2m
1.4 SPF
24.10.05
1f 3m
1.5 SPF
12.11.05
3f 6m
1.6 SPF
27.12.05
3f -
9/10+/-(FetA+/-) x 15D2(FetA-/-)
(28.10.05 - 11.01.06) 
2.1 SPF
23.11.05
5f 12m
2.2 SPF
19.12.05
9f 8m
57/58+/-(FetA+/-) x 15D2(FetA-/-)
(07.02.06 - 27.03.06) 
3.1 SPF
28.02.06
10f 4m
3.2 SPF
30.03.06
3f 6m
74+/- x 106D2
(05.05.06 - 19.07.06) 
3.3 SPF
04.04.06
6f 5m
4.1 SPF
30.05.06
4f 4m
4.2 SPF
28.06.06
5f 5m
5.1 SPF
02.09.06
5f -
5.3 SPF
22.10.06
2f 4m
5.2 SPF
25.09.06
4f 2m
5.4 SPF
30.10.06
1f 3m
109/110+/- x 106D2
(19.07.06 - 23.11.06) 
125/133+/- x 106D2
(30.11.06 -) 
N1
N2
N3
N4
N5
6.1 SPF
11.01.07
4f 3m
6.2 SPF
21.02.07
- 3m
6.3 SPF
01.03.07
4f 3m
N6
Figure 4.1: DBA/2 backcrossing pedigree. Beginning from the second
C57BL/6 backcrossing generation as shown in Figure 4.2, this pedigree shows
every DBA/2 mating event. Litters are indicated by a box, showing date of
birth and numbers of male (m) and female (f) pups. Number code: the first
digit indicates the mating cage; the second digit counts for the litter number
of the mating cage. N = back crossing generation.
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Figure 4.2: C57BL/6 back crossing pedigree. Beginning from the generated
chimera, the pedigree shows every mating event. Litters are indicated by
a box, showing date of birth and numbers of male (m) and female (f) pups.
Number code: the first digit indicates the mating cage; the second digit counts
for the litter number of the mating cage. N = back crossing generation.
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Fetub Genomic Sequence
>Nt_039624contig
Mus musculus chromosome 16 genomic contig, strain c57BL/6J. 
gtgaccagattgacttctgatgatttcacagctattcacacggaattagaaaggatacct
gctttgtgctaacacggctataaaacaggatgacgggacctttgatgcagccgccctcct
ctccattccacgtgagcgtcctggacttacccatgcccagcctgctgcgggcagccagag
cctttctgggtcactgtgtgtacagtactgactatggtgagattcagcaataaagccacc
tactgagtgacagccttgggcatcagcagctctgggtggagaaggccctgtgcagggaag
ccacagcctatgggtgggacccaaagtgcgggcagagcattgggaaaagcccaggcagaa
acaaagtactgggcggctccttggaaagacacggaacctaattagagcttattctctcta
ggaccttcctctaattcatagttagggtgtatgtcagccctgaaactcagctaagcaggg
tattattcctggagttctgaatgatggcgcactctgtttgcaagatataaaagggcagtc
agagggagaagctgccatcatcctttgcagctccatcgggaacacctggagaggatCCCT
CCAATTTGTTAATTAACAAACAAGCACCTTGTTTATACACCAGTTGCTCCTGTGAGTTGG
TCTCCTGGCCGAAGCGACTCTGGGTCCTCAGGAAAGCCTGTCTGTCAGAGCTGCAGGACT
GGGCCCCACCTTCCGTGTTCCTCCCTGTCTTAGATCAACGGGACTgtgagtatgtgacat
gcgtggccatcttccctgcccactccttactttttagactcttttggggggggggggagt
acagaggccaaatccatagccaagcacagttcactggtcctcacacccagcccacgtgtg
tgtggaaaatgcttcctgcattcccattggtgagtactgaactggaattaaaccccaggc
ctgcgtgaacccagcgtctgtattagtggcctcttcacaacaaggatttttacgggaaat
ctcactcatgatgcaataggatcacgttcccccgggggggcatggtggatagatctgtgt
gattcaagttccggaaatctcactcatgatgcaataggatcacgttcccccggggggcat
ggtggatagatctgtgtgattcaagttccgtagagccaggttctaggagctgcccctgct
agagatggaatggcaccctgtgcagagaggggggcagagtgccctcccatcagggctaaa
cgggcccttagtaatcgcatggttgaaagccctacacagttgaggaaattgggcttaagt
gttacatcgctagcctagctcacgcagaccagggctgaagcagggtcctggtcaaagttc
agtttaccatgtgatttagcatccttacagcatctttttaccccgtttgcatctgtcttt
cattaaaattgcaccaatggcttctacctaagtgtactgggtacatttcctcaggcattg
gacactccagcccagacccgacagaggtatgttcactgctggctgaaactaaatctctgc
tgaacctcagagtttggatatctgattttttttaactgataaaggaaaacttaagcacat
ttaaattgaaaaaaattaaagcattcattaatttatgagtcccagtattgtgggagggta
aacttgtacaatttagctgtagaaagaagggaagataaatgaattttattggttagtgta
gaaagctcctgtcttgaggttattatttatttgtttgttgtttgtttatttggtagagat
ttaaattccagagcctccacaatctaatggtctcccaatttgtgttgtttttcttaaagt
agccatttctggcttcgatacccatttttctcgaattattcccatttgaaaacacaactg
ggagcgtgtgggggaaaaaaaatttggtaactcagggttggaatcattctaaacaacacg
tggcatgagccaacccagaaaaacaggtctttaaagatatttctaaattggaaaaaagaa
agaaagaaagaaagaaagaaagaaagaaagaaagaaagaaagaaaacacaaccaagagct
cccttctgtagaactgtaatcttcagatttgggtttcataatcaatctttactaaccact
tgtttacggaagactaaaaagtgggcgtggcttcttattaatgtggtccatcctgtgctg
tgctgctgtcaccggatccttctcacccttctggaggcctggagggcctctgggaacagc
tttcttgctgcgtcatgcgtgggcgggaggcgggaggcaggaggaagaactctgcctaac
aaatgtactcccctgacatgggcatgccccacccctgagaacagagcccttgggacttaa
tctctgtaaaggcgccacctctccacaggtttcataagcgttcgttttctgagctttggg
aacgtgttcaaagcaCACCAGACTTGCAAAGCTCTTGATTCCGGACAGCTTACCTTGATT
CCTGACATTGTGCAGTGGCTCAGCCAGAACCTGTGAGTCACAGGTAGCTGCTGTGTTACA
CAACATCTAACAACGTCTAGCCTTCTGCGATTTCTGGTGCAGGGTCATGATTAGTGCATT
TGACAGATTTGGCAGAGTGGCTTACAGTGGgtaagtggcttctccacatcggctggttgg
tagctgaaagagtagctcacacagtgttctaagcatctgtgtggtgacaaaaatattttt
acatttatttgtttatttttgtgcagaggtggggtgggtgggccagagtgcagatgacac
tgcactctggtcagaggacatcgttcagcagtcggttcttccctttcactgtgagggtat
caggagttacattcaggccaccaggcttggcagcaagcacctttaggggctgagccatct
cactcgctttgatgaaaatcttctaaaagggaaggctcctgtgctgtttcttgtattgat
tcattcaggatttttaccctttctgagccctagtattctcccctggttggacttggctaa
gttttctttagagttttcagtgagtgtctatactaccactaagttagtgagtggatgctg
ttacctagttgtctatgagtagctatcaaatggggtggggggtggggtgggggggaagga
atctgtgttctgctcaactataatacaattacatttagcatcataaatttaagtttttta
gtaagtttattataaaattaacttttcaatgttagctaaaaacataagtcagcatattta
agtttaatatgtaatcaatgttttaagtaaatttaggaacttgagcaatgttaacagcct
tcttttgcttggttcactcgtgtcagccatagcttactgcatattggattttcatctaga
ccagaggagcatttctttccatccaaaatatttgggccctcttatcaggttcccatgaaa
agtctcacagactggtgtccttatttataaacacagacatttccaaaatatatttgtgaa
ttaaaaataagctctactcaggaaaactcttatattctctagtagctgtagggacctgtg
118 APPENDIX
tttgaaatagtattgaccccaaagctttggagtcttcaagatactctgtgtattgagggc
ctaccagatgggtacctgtggatagagcagaacctctgtctattgaacacagaaagcctg
ggcaggggtggagatggaggtatggaatgaggtattgcttaccttagggaatgctttaag
ggacagcctgctatgtaggctcccttcctgacttagacctttgctttcattgttgatatc
tctctctctctctctctctctctctctctctctctctctctctctctctcccccccccca
cccccgtgtgtgtgtgtttgtagtagaaacatttttaaaaaaataaatggcctgtggctg
tagctcagaagtacaatgtttgcctggtgtaagtgaggccctggtttgatgcttggcatc
atgcacaatgtgtgtgtgccatttatggaggtaggtacccgcaatcccaggaatttgagc
agctgaagcaggattgcaagttccatgccagactgggaaacttattgaggtcttgtctca
aaataaaagttgctgtgatgtagcgctatgaaagcacgtccccagcacatatgaggccca
gccctagagggaaaggagctttgaaagatacctgatttagtcaccaggtatggtgatatg
cacctgtagtcccagtagatgcaagaggattgcgagttcaaggccagctaccgaacacat
ttaaggccctgtcaaaacaaaaaataaattgcttttcatatatccccaataagcagaacc
ttcctgggatctgaactgaagctcagaaagagaggcaagaaccatgatccgtcttgatgg
ccaccattatctttctcttgacagtgtcaggtcttggtctcttgatgaatttacctgtag
gtgcacaaaaggaagactagacctagagtgtgttgggagaacttttggggtctccttagc
tttccccaccttaaatacaattctgagatgaagcattttcctgtcctatacaggaactag
aaagggacacttctgagtagtgcttgtattcagttccagttggattaggactctccatct
ggacaagacagaagccaggtctcccatgtcttgatcaaacatttttttataattcctggg
aaagggttaggaaacttggatttatttacacgaaaggcatgctccggatccaaggttaga
acactgacaaatccaatccaaaatattgactcaaaaactgctgtgtttggatagaggtgg
cctcagggcatggtgtttcaagtcctagtaggctattctgttgcagttataaagctgctc
aagtgaaccttgaggccccacggcagggctcgtcctggcagctctatactgacacatcct
ggatctttttttttttttttttttttttttttccgagtttgttttttttttttttttttt
tttttccattttttattaggtatttaactcatttacatttccaatgctataccaaaagtc
ccccatatccacccacccccactcccctgcccacccactccccctttttggccctggtat
tcccctgtactggggcatataaagtttgcaagtccaatgggcctctctttccagtgatgg
ccgactaggccatcttttgatatatatgcagctagagtcaagagctccggggtactggtt
agctcataatgttgttccacctatagggttgcagatccctttagctccttggctactttc
tctagctcctccattgggagccctatgatccatccattagctgactgtgagcatccactt
ctgtgtttgctgggccccggcatagtctcacaagagacagctacatctgcgtcctttcta
taaaatcttgctagtgtatgcaatggtgtcagcgtttggatgctgattatggggtggatc
cctggctatggcagtctctacatggtccatcctttcatctcagctccaaactccgtctct
gtaactccttccatgggtgttttgttcccaaatctaaggaggggcatagtgtccacactt
cagtcttcattctccttgagtttcatgtgtttagcaaattatatcttatatcttgggtat
cctaggtttggggctaatatccacttatcagtgaatacatattgtgtgagtttctttgtg
aatgtgttacctcactcaggatgatgccctccaggtccatccatttggctaggaatttca
taaattcattctttttaatagctgagtagtactccattgtgtagatgtaccacattttct
gtatccattcctctgttgaggggcatctaggttctttccagcttctggctattataaata
aggctgctatgaacatagtggagcatgtgtccttcttacctgttggggcatcttctggat
atatgcccaggagaggtattgctggatcctccggtagtactatgtccagttttctgagga
accgccagactgatttccagagtggttgtacaagcctgcactcccaccaacaatggagga
gtgttcctctttctccacatcctcgccagcatctgctgtcacctgaatttttgatcttag
ccattctgactggtgtgaggtggaatctcagggttgttttgatttgcatttccctgatga
ttaaggatgttgaacattttttcaggtgcttctctgccattcggtattcctcaggtgaga
attctttgttcagttctgagccccattttttaatggggttatttgattttctgaagtcca
ccttcttgagttctttatatatgttggatattagtcccctatctgatttaggataggtaa
agatcctttcccaatctgttggtggtctttttgtcttattgacggtgtcttttgccttgc
agaaactttggagtttcattaggtcccatttgtcgattctcgatcttacagcacaagcca
ttgctgttctgttcaggaatttttcccctgtgcctatatcttcaaggcttttccccactt
tctcctctataagtttcagtgtctctggttttatgtgaagttccttgatccacttagatt
tgaccttagtacaaggagataagtatggatcgattcgcattcttctacatgataacaacc
agttgtgccagcaccaattgttgaaaatgctgtctttcttccactggatggttttagctc
ccttgtcgaagatcaagtgaccataggtgtgtgggttcatttctggatcttcaattctat
tccattggtctacttgtctgtctctataccagtaccatgcagtttttatcacaattgctc
tgtagtaaagctttaggtctggcatggtgattccgccagaagttcttttatccttgagaa
gactttttgctatcctaggttttttgttattccagacaaatttgcaaattgctccttcca
attcgttgaagaattgagttggaattttgatggggattgcattgaatctgtagattgctt
ttggcaagatagccatttttacaatgttgatcctgccaatccatgagcatgggagatctt
tccatcttctgagatcttctttaatttctttcttcagagatttgaagtttttatcataca
gatctttcacctccttagttagagtcacgccaagatattttatattatttgtgactattg
agaagggtgttgtttccctaatttctttctcagcctgtttattctttgtatagagaaagg
ccattgacttgtttgagtttattttatatccagctacttcaccgaagctgtttatcaggt
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ttaggagttctctggtagaatttttagggtcacttatatatactatcatatcatctgcaa
aaagtgatattttgacttcctcttttccaatttgtatccccttgatctccttttgttgtc
gaattgctctggctaatacttcaagtactatgttgaaaaggtagggagaaagtgggcagc
cttgtctagtccctgattttagtgggattgcttccagcttctctccatttactttgatgt
tggctactggtttgctgtagattgcttttatcatgtttaggtatgggccttgaattcctg
atctttccaaaacttttatcatgaatgggtgttggatcttgtcaaatgctttttctgcat
ctaacgagatgatcatgtggtttttgtctttgagtttgtttatataatggattacattga
tggattttcatatattaaaccatccctgcatccctggaataaaacctacttggtcaggat
ggatgattgctttaatgtgttcttggattcggttagcgagaattttattgaggatttttg
catcgatattcataagagaaattggtctgaagttctctatctttgttggatctttctgtg
gtttaggtatcagagtaatagtggcttcataaaatgagttgggtagagtaccttctactt
ctattttgtgaaatagtttgtgcagaattggaattagatcttctttgaaggtctgataga
actctgcactaaacccatctggtcctgggctttttttggttgggagactattaataactg
cttctatttctttaggtgatatgggactgtttagatggtcaacttgatcctgattcaact
ttggtacctggtatctgtccagaaatttgtccatttcgtccaggttttccagttttgttg
agtatagccttttgtagaaggatctgatggtgttttggatttcttcaggatctgttgtta
tgtctcccttttcatttctgattttgttaattaggattttgtccctgtgccctttagtga
gtctagctaagggtttatctatcttgttgattttctcaaagaaccaactcctcgtttggt
taattctttgaatagttcttcttgtttccacttggttgatttcactcctgagtttgatta
tttcctgccgtctactcctcttgggtgaatttgcttcctttttttctagggcttttagat
gtgttgtcaagctgctagtatgtgctgtctcccgtttcttcttggaggcactcagcgcta
tgagtttccctcttagaaatgctttcattgtgtcccataggtttgggtacgttgtggctt
cattttcattaaactctaaaaagtctttaatttctttctttattccttccttgaccaagg
tatcattgagaagagtgttattcagtttccacgtgaatgttggctttccattatttatgt
tgttattgaagatcagtcttaggccatggtggtctgataggatacatgggacaatttcaa
tatttttgtatctattgaggcctgttttgtgaccaattatatggtcaattttggagaagg
tcccgtgaggtgctgagaagaaggtatatccttttgttttaggataaaatgttctgtaga
tatctgtcaggtccatttgtttcataacttctgttagtttcactgtgtccctgtttagtt
tctgtttccacgatctgtcctttgaagaaagtggtgtgttgaagtctcccactattattg
tgtgaggtgcaatgtatgctttgagctttactaaagtgtctctaatgaatgtggctgccc
ttgcatttggtgcgtagatattcagaattgagagttcctcttggaggattttacctttga
tgagtatgaagtgtccctccttgtcttttttgataactttgggttggaagtcgattttat
ccgatattaaaatggctactccagcttgtttcttcagtccatttgcttggaaaattgttt
tccagcctttcactctgaggtagtgtctgtctttttccctgagatgggtttcctgtaagc
agcagaatgttgggtcctgtttgtgtagccagtctgttagtctatgtctttttattgggg
aattgagtccattgatattaagagatattaaggaaaagtaattgttgctcccttttattt
ttgttgttagagttggcattctgttcttgtggctgtcttctttttggtttgttgaatgat
tactttcttggttgttctagggcgtgatttccgtccttgtattgcttcttttctgttatt
atcctttgaagggctggattcgtggaaagatattgtgtgaacttggttttgtcgtggaat
actttggtttctccatctatggtaattgagagtttggccgggtatagtagcctgggctgg
catttgtgttctcttagtgtctgtataacatctgtccaggctcttctggctttcatagtc
tctggtgaaaagtctggtgtaattctgataggccttcctttatatgttacttgacctttc
tcccttactgcttttaatattctatctttatttagtgcatttgttgttctgattattatg
tgtcgggaggaatttcttttctggtccagtctatttggagttctgtatgcttcttgtatg
atcatgggcatctctttttttatgtttgggaagttttcttctattattttgttgaagata
ttagctggccctttaagttgaaaatcttcattctcatcaattcctattatccgtaggttt
ggtcttctcattgtgtcctggattacctggatgttttgagttaggatccttttgcatttt
gtattttctttgactgttgtgtcgatgttctctatggaatcttctgcacctgagattctc
tcttccatttcttgtattctgttgctgatgctcgcatctatggttccagatctctttcct
agggtttctatctccagcgttgcctcgctttgggttttctttattgtgtctacttcccct
tttagttctagtatggttttgttcatttccatcacctgtttggctgtgttttcctgcttt
tctttaagagcctgtaactctttagcagtgctctcctgtaaatctttaagtgacttatga
aagtccttcttgatgtcctctatcatcatcatgagaaatgtttttaaatctgggtctaga
ttttcggttgtgttggggtgcccaggactaggtggggtgggagtgctgcgttctgatgat
ggtgagtggtcttgatttctgttagtaggattcttacgtttgcctttcgccatctggtaa
tctctgaagctagctgttttagttgtcactgttaagagcttgttcttcaggtgactctgt
tagcctctatgagcagacctggagggtagcactctccttagtttcagtgggcagagtatt
ctctgcaggcaagctctcttcttgcaaggcaggtacccagatatctggtgttcgaaccag
actcctggcagaagttgtgttccactcactagaggtcttagggtcccgtggggagtcccg
tgtggacccttgcgggtgttgggcaagactctgctggcaaggtagcccggggctcgagtc
tcgagtcgagcggaggggacttgtgccccagatcaggcccgggtagcctgcttccctatg
taccgcagtctcaagttccgcgcgattggattggggcaggcactgtggtccactcaccag
aggtcttagggtcccgtggggagtcccgtgtggacccttgcgggtgttgggcaagactct
120 APPENDIX
gctggcaaggtagcccggggctcgagtctcgagtcgagcggaagggacttgtgccccaga
tcccacatcctggatcttgttccccacagAATGGGCCTGCTCCGACTTCTGGTGCTCTGC
 M  G  L  L  R  L  L  V  L  C 
ACCCTGGCTGCATGCTGCATGGCCCGCTCTCCCCCAGCCCCACCCCTGCCACAACGCCCC
T  L  A  A  C  C  M  A  R  S  P  P  A  P  P  L  P  Q  R  P 
CTCTCACCTCTGCATCCTCTGGGCTGTAACGACTCTGAAGTGCTGGCAGTTGCAGGATTT
L  S  P  L  H  P  L  G  C  N  D  S  E  V  L  A  V  A  G  F 
GCCCTGCAGAACATCAACAGAGACCAAAAGGATGGCTATATGTTGAGCCTTAACAGAGTG
A  L  Q  N  I  N  R  D  Q  K  D  G  Y  M  L  S  L  N  R  V 
CATGATGTTCGGGAGCACTACCAGgcaagtgacaggttgtggggcagcatttgggcaggc
H  D  V  R  E  H  Y  Q 
tgcaggcactagccagggggtggcaacttggtgctacttgtcaacaggtactttctggtc
tagaaacagaatactctgccgtcaccagcaggtgtgctatgacactcttgctggccatag
gaatggtgacaagagtgtttctactctgtcccaggtccaggcttcaggagtatagcagag
catgtatcacacacaggagcttaggttctcccaggaagatgctattggtctagttgtcct
ggatctgtttcatgtgcaatgccgtatttctctaacccttatcatagGAAGACATGGGAT
                                               E  D M  G  S 
CTCTGTTCTACCTCACATTGGATGTCTTAGAGACTGACTGCCACGTGCTCAGCAGGAAGG
  L  F  Y  L  T  L  D  V  L  E  T  D  C  H  V  L  S  R  K  A 
CACAGAAGGACTGCAAACCGAGGATGTTCTATGAGTCGgtaagtgcctgttcccaggggc
  Q  K  D  C  K  P  R  M  F  Y  E  S 
ctgctcagtgtctaccgtctgtttcatcttcattatctcccaggcaacaggccagtgtgc
caattctaatactggaggaagagccaagtttagtcagggtagggaggggtcctcagactg
gggccttgctgactagacttgaaaagtttcccccaaattattttctaccctaagaatctt
tggcagctgagccaatgtttatagtctcgggggggggggggcaaagacagagattgatta
attgattgattgattgatttctggtgtttgaggaaggtaggtagacagcagcaataatgg
agtatagcttgtgttcttttgtttggttttatttgaatgaatatcaatatgaggttttca
gataggaaagaggacagctttcagtgtgggtactgtcaggggcttcctgggcataaaact
gaacggcctcagaactcatcctttctccttttaaaaaaatattttatttttctatacata
tgggtgccttgtgtgcatgtatgtgtatgcaccacgttcgtgcccacagcgaccagaggg
tggcaaaagacccaccccaccccccaccccaatctccaaccctagtactggagtttcaga
tggttatatgccacctaatgggggcactgagaaccaaacttgggttgtctagaagaatcg
tgagggtcactaagccatctttccagccttgagcttggcctttcaaaatggccactggca
agacttgaaaccagtgcagtcagcttccacctgactctcagtgattctgggatctctttc
attcactgatgcatggaaggtgtatgacatggaagacaaggtgagatcttcagtggtttg
aagtaaactttttgatcaagatcaccttttgtagttatttgaccaaacattccgacctgc
acctgttttttgtttgtttgttttgtttttaaagcaaaaacaaacaaacaaacaaaaaac
aaagaacaaaaaacaaaacaaaacaaatcccccaaaccaaaaaccaaataatagaaaaac
cagtcttatgccttcttgttatagttggtttagtgatacgggccactcacagagatatgt
atgctcactcagggacacacaggttaggagtttatttcacgtgtaatttcaaacttcaag
ttcctgaccaggggattttgctctgggcatgatttggaggccccacttctcgctgtgtgt
tgggcaccaggcgtgggggaataaagggagtgggagaaaaccccgcatcccaccagagtt
ccggttctctgggtaggcagacatgggaggactgctgcatgctttccacatggccccggg
tgggctgtgggaagctatggacccagcccagggggatgggcaaggggcattccaaggtct
ctgggcctcatggaggccagagataacaggttgtcaggcatcccagacaccactggacac
cgcagaagagctgagaacaaaatgggtgcccctggggctgctcggtcagccctgggcccg
aagggaggagagggcaggaggagagggggtactgggtggttcccatgccggtaagagtct
ttggtctggtccatggctggagctcaggaagaccttcgggcggggttaggggaaagccta
tcccatcgttcaagcactgcaggcctgatgaacagagatagtctatggttttagagattt
attatagaaaggcaaggggaaagagagagagagaggctggccatggccacgtggagagag
gggcttagtgagagagagaaggagggctagagatgagagtaagaaaggcaagagcttaga
gagaggaggggccaagcagttccttctatagtgggctgggctaccttgctgttgccaggt
aactgtggggaggagcaaacctggctataggttaactttgggggtggagtctagccagaa
tgttaggagcttggggctttatctgtgtgactgatagtcacagaattatggagttgggcg
ctctgcggtgtcaggcacctgtctctgggaatgtggctcagtgttctgcagagttttcta
ctgggacgtaggagcaagcttcattcaatcaaaacaggctgcctttcacggccccacatc
tgtgcttgtctctgaccttgctacctcctacctgtgagtccctagtgcccatattcactg
gcatcaggatagaacgaggacatgccatgctgacgtggccatggagcagggcaaagggaa
gctggttctgatccatttctgcagttagaactcaggttggcgatccacgcccgagtgtga
ggagcctgggaaggtagctgtgtcccaggaaaacatggaagagtctgatgctaaagagtt
ctccccaccccaaacacagaactggatttaagtttcacattacattaaaatacaattcta
cttgggggaggggtggtgtttaacctcgtggttctctgcagcatgccatcccatcgagta
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catttgttttttgttttttcctagGTTTATGGCCAGTGCAAAGCAATGTTTCACATTAAC
                        V  Y  G  Q  C  K  A  M  F  H  I  N 
AAGCCAAGAAGAGTTCTCTACTTACCTGCTTATAACTGTACACTTCGCCCAGgtaaacat
K  P  R  R  V  L  Y  L  P  A  Y  N  C  T  L  R  P  V 
caagacggttttgtacatcttgtcatcaaaaaacagaaaagagaacttaactagggcctt
tgatgagttggcaagcaatctctcctctcttccgctgtatccatcacagcactgcacaac
actccatcattgcctctctactgacattccctccatacttctcctcccaggggacagcct
tcctaagtcactgtcaagagctctgtcctgatccagatcctagatgctcattcttctgtg
agtgacacaatagcaatagctggtcccaggatcccttctatctgtcccactgtcctgaca
cccttccagctggctgttgtgttgtcagaacacgcactacactttcctgtgtctgcactt
gtttgagcctctccctctgctgtatgcccttgatggcctctgtatcagaactcatacccc
cttttatttaaaacaaaaaacaaaaaaacacaatgtttttgagatgccctttactcaaga
aaggaatggttctttcctggtgtaaatttttctcactttggctaaaacactcatccaatg
cagaacagaacatgcacaatcttgacttatagtcttatatcttctatcatatggcatgca
tgtccctctgccccagtaaaagacttcctaatttatataaagttttggaggttattacca
ttgctgaataacaggggaaaaataaggctggaatgaataggccattcattgaaataagtg
tgtgcactcttccctctggagcctgctttttacaagagagggtcttggaaaagtgggagc
ccattgcacgggaaaatgggaaatatctacctagcagcttgtgctacctcactgtgataa
aggggccagcctgaaatcaatctggggacttctggaaatggtggcagtgatacccatagg
tgtcaggagttggtgacgagggaggcacagtggcaggctgtgggcacagctctcccgcca
tcttcctccacctccaaacatttattagggaagacaatgaattttctgacaacaccccgg
ggcaaattccctggcttgatgagcacacatttgtcctctccagctcctcctgtcatggtg
tcatccacttgcttgacaggcctctactggctcatcagtctgtgttaggtttgctcgtgg
tgctgaggaccaaggccatgaagtagctcctgacaataatgaagtgtctatgggaacagt
gatgggaaaggacctggagctagggaggggactgatgtgtctactgttttgacacaggaa
cacaatgctgtcatctaccatgttcacacttgataactgtgtaatcatgttgcaaaaaaa
aaatctcgtaatgttttaagcatatttacaatcccatgataggtcgcattctttgtggtc
tttaacactgtgctgtccacagactactggttggccatgccccatgtggttctaaacaaa
attcctatagtaaataagtccataagagggtaaggctatctcattttgatttctttttaa
ttacaaaaggagcagggcttagagactagatgttagctcaggtggcagagtgccaagcat
gcgtgaaggccagtttggatgctagcacctagaagccaagcatgatggcacatgcctacc
agcctagtccctggcaggaacgaaggaatgaaggaacaaagggaaggaaggaagaaagga
aggaaggaaataaaaataaagtactacttctgctatcatattcccaacaactaaatgctt
tctaagaaaaatgtctttctcactgaatccttgccagtactggatattatcattttagcc
cagtctttggctctggtatagttgtatgattatgactattattaggactgaaaattaata
atatttataaactattctcatcaatagTTTCCAAAAGAAAGACTCATACAACGTGCCCTG
                             S  K  R  K  T  H  T  T  C  P  D 
ACTGCCCTAGCCCCATTGACTTGTCAAACCCCAGTGCTCTGGAAGCTGCCACGGAGTCGC
  C  P  S  P  I  D  L  S  N  P  S  A  L  E  A  A  T  E  S  L 
TTGCAAAGTTCAACAGTAAGAGCCCCTCAAAAAAGTATGAACTCGTCAAAGTCACCAAGG
  A  K  F  N  S  K  S  P  S  K  K  Y  E  L  V  K  V  T  K  A 
CTATGAACCAGgtaaagctaaaatgcccatgtcagttacacagtcgtcactgcagggtct
  M  N  Q 
tagcctggttgggggtagggggtggggagggggactgtccaggcgttctgtctgcctaga
acctgcgatcctttcctatatctcaattaatttctaggacagccactgtgcattcagtca
tattacagctcttgctattccttggaatttgtatgaatagcaggtgacttactttctctc
tctctctctctctctctctctctctctctctctctctcgacggggtttctctgtatagcc
ctggctgtcctagaactcactctgtagaccaggttggcctcgaactcagaaatctgcctg
cctctgcctcccgagtgctgggattaaaggcgtgtgccaccactgcccggcctatgactt
gactttctttttttttttttttttttatttttatttattttttttttaaagatttattta
ttgattatatgtaagtacactgtagctgtcttcagacactccagaagagggagtcagatc
tcattacggatggttgtgagccaccatgtggttgctgggatttgaactctggaccttcgg
aagagcagtcgggcgctcctacccactgagccatctcaccagcccatgacttgactttct
taaagcaagaagattcttagttttatgtgagcttgggatgaaataggttcagcatttttc
tggctgattatggaccctttagcaagacaacttttgcttctttaaggcctggggtaggtg
ttgagctttataggttgtggaataagagattcatttatatttcaattgtgtggatagctc
ttgcatataaataaaactaaaagcaaagctttatttaaaaaaataagcaaaccaaggcac
cgatttttatgggttttttcttttaatttcatttcatgtgtgttggtattttgtctgtgt
gagggtattagatcccccttgaactagagttatggacaattgtgggtgccaggaattgaa
ctcaggtcctctggaaaaacagtcagtgctcttaaccactgagccatctctccagtcctg
attcatattttctaaatagcagaattactgacttggtcttgtgcctgtggggacttcagg
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aacagtgaacttgggtgttgacagtgcctcagaatcagttctatacaaggactgttgtca
atcctgagtttcccctggggtaagattttaatgtcttaactcttatttcatggcagTGGG
                                                        W  V
TGTCTGGCCCTGCTTACTATGTGGAATATTTGATCAAAGAGGCACCATGTACCAAATCCC
  S  G  P  A  Y  Y  V  E  Y  L  I  K  E  A  P C  T  K  S  Q 
AGGCCAGCTGTTCGCTCCAGCACTCTGACTCTGAGtgagtgttcccgactgactgtaca
 A  S  C  S  L  Q  H  S  D  S  E  P 
atctgtatgtgttcacaggtcatcagtacttgtggagcacaaattcccctggggggtgtc
acaagtcatcccatgcttccctcccctccccaagcagttagaaactgggcagctcttgat
gcagtgataggatttatttgattctaagtgtggtttttatgtaatataattgcaaaaaaa
aaatcatgagaggacttggaagacagcctggtgttccattctttgggccactcttcacaa
tgtggctaagaaaagtaagggatgagcaccccagcactatcagaaagatactgggaatgg
aatcagcgtggtgtgtttgagcaccactgggcaacggtacttttccttgtttatgtatag
tggggttttactgagctacagtttacatacaataagatttatcatcttaaagtagataat
tccatttttgttatatattcacagacctgagtcaccataaccacctcatatttttaagaa
aaaaatacttttattagctctcagaagaaaccccatctctattaagttaacccccgttgc
tgccctaagaagaccctagaaactatgaatctgatttctgtcttaatagctttgtctatt
ttaacacttcatacaaatgggatcatgcagaggattggggtggggagagatatttatttg
aataagaaacttgaccgatgaactccatcagactagccaatgaatgagatcggtgaagtg
cagcccccaaagactggccctctgtgctccactccatgccagcacaagaaggtctgcgag
atttgatagctcatgaagttctacctagcatggaatatccacctgttcttgccacaggtg
catgcagtttctctagaaggttctctgagagcctctgagccatggcattaaagaggaaga
agggaagtcagggccaccattttacactaatggattttcccacctggagaaatttctggt
cttcatgtgaccaaggaaacatatagaagataggctctgtttgaggcatgcagtttcaga
gggttagcatccatggccatcatggtgcatagcatggtagcaggcaagaaggcatggtac
tgcagcagtggctggcagcttcatcctgatccacaagtaggaagcagagggagctaaatg
ggttcttaaaacctcaaatcccaatcccagtgacacatcccctccaaaaaggccccacct
cctaatccttcccaaccagttctaccaaccagggaccaagcattcaaatatatgaggcta
tagagccactctcattcaaaccaccacatatggattcactgtaaagaagaaacttagaga
tatatgaaaggaaagtttcaatgttttataaaaaaaatagattcaatctagttgtttgac
aagagactttattaaatacagaggagtactaggtagccattataaagataataattgaag
aaaaaagactatcaaatgtcatacaaaagtttttacaatatattgttcagaaacaaaata
gtttttaaaaatatcatatgcaatatgatcatagagtttaaaagaaaaatatacgtgcat
agggaaaagattagaagaaaaggaccaaaagattacaggtagtgagagccatgcatggga
ttacaggtcatggtcctttcttttgtttgtatagttctaaatagtaatttattacattta
taataaaacccctacaatttcattttcaaatagacagaaggttaagggactgagagtgtt
tttgctagagaagacaaaccctcattcagaatacattaagggctcctgtagagaagaaaa
caccaagcttctaattggccaagggcagacctagggccaggcagtggacagtatgtagac
acagggaaaccttcctaaaaacctcagttcccattgctagaatcgagctgcactcaattg
tctttagataattcacagggacctggctgggagcccgccattttccaaggcaggagcaga
aaaccatggcacagctatgccttacgtaagcggaaagggaggggcttgcatctgcgctca
cctgtaacttaatgcccacatgatgcctttccttcttttagCCCGTTGGTATTTGCCAAG
                                           V  G  I  C  Q  G 
GTTCTACGGTCCAAAGTTCTCTGAGGCACGTTCCTCTGATCCAACCCGTAGAAAAGTCTG
 S  T  V  Q  S  S  L  R  H  V  P  L  I  Q  P  V  E  K  S  V 
TCACTGTGACTTGTGAGTTCTTCGAATCTCAGgtatttatctttttaaaaacaatgttat
 V  T  C  E  F  F  E  S  Q  A  Q 
tgtgtttttgcacaacgtaagcgtattgagcacatgtaacatggcacacatgtggagtca
gaggataacatggtgtagtttgttctttccttccacctttacatggggtctggggagttg
aactcgggtcgctgggcttgcaagagcatgatgttccatgctgagccctaccattctaac
cgcccccactctgtgtttttcaatgaaatcaggtgatgtgtttctaggtgcctatttccc
aacctcttctggcttcccccaagattcagaatcactttacttaggctctgtaaacccaca
catataggagatgagcgtaccctactgttttaggtccagtggcagcaggtgcagaataag
ggaagaacactcaggaacaacacagtgaactacacacttgcatagcctaagccttcaagg
tgctaaatccagtgtctccaagaagcctctctcacctcagagagaatcacttccgtgaac
atgttcattctctctccacagacactaagttcttcctgagacgtagcctgatctagtcag
acaggctgcctgggcttcctccctgctctgtccctataagctctgctgccaccccttacc
tgtctgggacttggtaccctcatcatctgcctgttgtgatatctaagaccagtgagaagg
tttggatgcagggcactatactgggtgtggcatgaaacaaacagtaaaagaggccacctg
ctgccactcctgggagcaaaggcaactccctggggaccctgagtacatcctttggcccct
ctgaaccactgctctgaagtgaacggcctcatgtccagcatctgcaggtcttagttctag
ctgtcccttacgtgttttgttgttgatctttctgtcaagaggcctgttcctgagctcagt
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ggttctcaactgcaggtggcaacacaggggtcacctaagaccattggaaaacacagatgt
ttacgttatgattcataagaaaagcgaggttatgaaaataatttcaccacaacatgaact
gtctcaaagggtcatggcattaggaaggttgagaaccactggtgtatctggcttctctaa
gcattcagaaatgctccaagcagagacaagtgtgttagcccaggcctggaaacccagcac
tcaggagatgaggttggaaatgatgaatctgagcctgggctagcttaagaccatgtaaca
aacatgcagtcacaaaacagctttgcctggtgtgggttatggcagggcattccctgtaga
cttctgcatctaacaacattgttatttcagGCTCAGGTCCCTGGAGATGAGAACCCTGCT
                                V  P  G  D  E  N  P  A  V  T 
GTTACCCAGGGCCCTCAGAAACTCCCTCAGAAAAACACGGCCCCTACCAGCTCCCCCTCC
  Q  G  P  Q  K  L  P  Q  K  N  T  A  P  T  S  S  P  S  V  T 
GTAACTGCACCAAGAGGATCCATCCAGCACCTCCCCGAACTGGATGATGAGAAGCCCGAG
  A  P  R  G  S  I  Q  H  L   P  E  L  D  D  E  K  P  E  E 
GAGTCCAAGGGAGGGAGCCCTGAGGAAGCCTTTCCTGTGCAGCTGGATCTAACCACCAAT
S  K  G  G  S  P  E  E  A  F  P  V  Q  L  D  L  T  T  N  P 
CCCCAGGGGGACACACTAGATGTCTCCTTCCTGTACCTGGAGCCTGGGGACAAGAAGCTG
Q  G  D  T  L  D  V  S  F  L  Y  L  E  P  G  D  K  K  L  V 
GTGGTGCTGCCTTTCCCTGGAAAGGAACAGCGCTCCGCCGAGTGCCCAGGGCCCGAGAAG
V  L  P  F  P  G  K  E  Q  R  S  A  E  C  P  G  P  E  K  E
GAGAACAACCCTCTGGTTCTCCCACCCTGAGACTCCCTAGCAGGGTTTCATAGGGCTATG
N  N  P  L  V  L  P  P 
GTCCCCAGCACTAAATGGGAGGTGGTGGGGATTGGGAAGGACACAGACAATGAAATGTAG
ACAGGCTAAtaaagtgtgtccttttgatgcttcttggcttcaacctgttgactgaaactg
gaaatgagactaaatgcccatgctggagcac
Figure 4.3: Genomic sequence of Fetub. Green letters indicate the cloned
mouse promoter sequence MP2 as described in section 3.4.1; red letters indi-
cate the cloned mouse promoter sequence MP1 as described in section 3.4.1;
bold black letters symbolize the cloned sequences for homologue recombina-
tion as described in section 3.1.1 ; capital letters indicate amino acids and
underlined capital letters symbolize exons.

Abbreviations
+/+ wildtyp (genotype)
+/- heterozygote
-/- homozygous knockout
Ahsg genetic symbol of fetuin-A
BAC bacterial artificial chromosome
cDNA copy DNA
COC cumulus-oocyte complex
DNA desoxyribonucleic acide
dpc day post coitus
E. coli Escherichia coli
ELISA enzyme-linked immunosorbent assay
ES cells embryonic stem cells
Fx x. inbred generation
FCS fetal calf serum
FetuB genetic symbol of fetuin-B
FSH follicle stimulating hormone
HRG histidine-rich glycoprotein
kb kilo bases
kDa kilo Dalton
KO knockout
LH luteinizing hormone
LPS lipopolysaccharid
M molar
MCS multiple cloning site
MLEC mink lung epithelial cells
NC negative control
Nx x. backcrossing generation
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ON over night
ORF open reading frame
PAGE polyacrylamide gel electrophoresis
PBS phosphate buffered saline
PC positive control
PCR polymerase chain reaction
RPM rounds per minute
RT room temperature
SDS sodium dodecyl sulfate
SPF specific pathogen free
TGF transforming growth factor
Tris tris-(hydroxymethyl)-aminomethan
UTR untranslated region
WT wildtype
ZP zona pellucida
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